Podcasts about Abbott

Most clinical research treats patients like data points. What gets lost when researchers stop listening to the people they study, and what does it cost the science itself? Niharika Singh is a biomedical engineer and pre-medical student with research experience at Genentech, Abbott, AstraZeneca, and the Keck School of Medicine, and a global ambassador with the United Nations SURGhub. She discusses the KevinMD article "Patient involvement transforms modern clinical research." You will hear the difference between treating a patient as a data set, engaging them as a collaborator, and inviting their emotional and lived experience into the study design. She walks through the Tiger Project hernia training across India and Ghana, what medical device design verification taught her about surgical research, and why AI in medicine is making patient voice harder to hear. You will hear a research methodology that treats the patient's voice as data worth collecting, and a case for defending human connection as AI changes how medicine is practiced. Partner with me on the KevinMD platform. With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Whether you need a sponsored article, email campaign, video interview, or a spot right here on the podcast, I offer the trusted space your brand deserves to be heard. Let's work together to tell your story. PARTNER WITH KEVINMD → https://kevinmd.com/influencer SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Two social media experts walk into Mysa Hus, and what comes out is a refreshingly honest take on the wins, the flops, and the algorithm mysteries nobody can fully explain. Alyssa Abbott from Olive and Vine Socials and Mary Clark from Pella swap stories about overworked carousels that flopped, lazy Saturday posts that crushed it, and why chasing every trending audio clip is a great way to end up in murky water. They also tackle the AI elephant in the room, and spoiler, authenticity wins every single time. Support the show - https://www.curiousbuilderpodcast.com/shop See our upcoming live events - https://www.curiousbuilderpodcast.com/events The host of the Curious Builder Podcast is Mark D. Williams, the founder of Mark D. Williams Custom Homes Inc. They are an award-winning Twin Cities-based home builder, creating quality custom homes and remodels — one-of-a-kind dream homes of all styles and scopes. Whether you're looking to reimagine your current space or start fresh with a new construction, we build homes that reflect how you live your everyday life. Sponsors for the Episode:  Pella Website: https://www.pella.com/ppc/professionals/why-wood/  Where to find the Guest:  Alyssa Abbott Website: https://oliveandvinesocials.com/ Instagram: https://www.instagram.com/oliveandvinesocials/ Mary Clark Website: https://www.pella.com/ LinkedIn: https://www.linkedin.com/in/mary-clark-9b45b2119/ Where to find the Host:  Website - https://www.mdwilliamshomes.com/  Podcast Website - https://www.curiousbuilderpodcast.com Instagram - https://www.instagram.com/markdwilliams_customhomes/  Facebook - https://www.facebook.com/MarkDWilliamsCustomHomesInc/  LinkedIn - https://www.linkedin.com/in/mark-williams-968a3420/  Houzz - https://www.houzz.com/pro/markdwilliamscustomhomes/mark-d-williams-custom-homes-inc

In this refreshing conversation, I sit down with Natalie Abbott, co-founder of Dwell Differently. She shares her powerful journey of seeking God through various religious texts and how, in time, He opened her heart in a profound way. Soon after, the Bible came alive to her, and she discovered that God's truth is not only accessible but deeply transformative.We explore the “why” behind Scripture memorization, along with the science of how our brains work—unpacking how God designed our neural pathways to be shaped, strengthened, and renewed throughout our lives. Natalie opens up about the joy of working alongside her sister, the weight that can come with doing work the enemy seeks to undermine, and the deep encouragement she's found in hearing testimonies of God's Word taking root and bearing fruit in people's lives.Memorable Quotes:On verse memorization: “If I'm meditating on it, if I'm memorizing it, if I'm allowing it to sort of saturate deep into my bones, then it's going to affect me, it's going to deeply and profoundly transform me because that's what God's Word does, and it's going to come out in my life.”“I'm going to pray, ‘God if you're there, show me who you are,” and that is what I did every single night.”“I thought, ‘that book has made me feel so guilty and so terrible for so long, I'm going to burn it.' And at that moment, the Lord just intervened and was like, ‘Natalie, all those things that you couldn't live up to, I did, in Jesus, I did that for you. Will you believe that?' And I gave my life to Christ and it changed everything.” “If God is speaking in that book, like really actually speaking, and we say that we believe it, how come it's building up dust on the side of our bedside tables?”“It's just a few small words, that you put into your heart and into your mind, and you allow it to be the guiding force in your day, you allow God himself to speak into your heart and into your mind. Man it is so powerful. It is so good.”“Anything I say that is good or wise or helpful, it's a regurgitation of what God's already said.”“In some ways what we do at Dwell Differently is like the feeding of the 5,000. How can I even possibly know what God does with all of that nourishment that He is giving to His people? I have no idea. I'm the guy with the two fish and the five loaves and I'm saying, ‘God would you multiply this.'”“Wherever God is calling you, the enemy is always going to have those super highways, negative super highways - he's going to use those, they are powerful tools, he has used them before, they work, he is going to speak those lies to you, and you have to turn right back around and say, ‘That is not true. That is not true.'”Show Notes & Scripture References:Psalm 23:11 John 3:1Psalm 139John 15:7John 10:27Psalm 16:3Since recording, Dwell Differently has recently moved away from their monthly membership model, but their mission and ministry will continue through their podcast, website, and social media channels. Dwell Differently: Overcome Negative Thinking with the Simple Practice of Memorizing God's TruthSocial media: @dwelldifferently, @nataliejoyabbottWebsite: dwelldifferently.com

David "Tank" Abbott returns for part 4 as the team quotes directly from Tito Ortiz's autobiography This Is Gonna Hurt and gets Tank's raw, unfiltered response to every claim. From Tito's glue-sniffing childhood hallucinations and shocking family stories to the infamous stolen check incident, training sessions where Tito claims he dominated Tank on the mat, UFC blackballing accusations, early weight-class politics, and more — nothing is off-limits.Tank breaks down Tito's version of their training relationship, sets the record straight on his own wrestling background and real street-fighting roots, and explains why he believes Tito's entire persona was manufactured. The conversation also covers Chuck Liddell's actual contender path versus hand-picked opponents, the "Tito Ortiz rule" at 205 lbs, and a tease into Big John McCarthy's book.This is pure, no-holds-barred MMA history from one of the sport's original street fighters and pioneers.If you want the real stories behind early UFC, the men who actually lived it, and zero corporate filter, this is essential viewing.Subscribe & hit the bell for more legendary interviews preserving mixed martial arts history. Drop your thoughts on Tito's book in the comments.0:00 start 0:49 MMA history podcast intro1:22 Joey Venti's guest introduction1:48 interview start 2:43 Tito Ortiz in the hospital 3:28 Prologue about sniffing glue 7:54 thoughts after meeting Tito Ortiz 10:50 Tito Ortiz requesting for 205lb weight class 13:38 running into Wanderlei Silva 17:46 Tito Ortiz receiving hand picked opponents 22:49 Tito Ortiz screwing over Dana White 26:08 mother becoming “Lady of the evening” 28:31 Tito Ortiz stealing a blank check book 31:51 Tito Ortiz stealing from Tanks home 34:20 becoming financially stable 36:35 1st book review  37:47 arrested for stealing a car 40:09 Tito Ortiz amateur wrestling career43:35 2nd book review 45:25 wrestling coach Paul Herrera  48:15 stealing “the Huntington Beach bad boy” name 52:15 3rd book review 53:50 Tito Ortiz training with Tank Abbott 57:17 Tank Abbott athletic background 59:04 learning how to wrestle 1:04:45 4th book review 1:07:17 advice from Tank Abbott to Tito Ortiz 1:10:56 street fight rumor with John Matua 1:16:22 5th book review 1:17:17 Tito Ortiz getting over on people 1:21:16 Tito Ortiz bringing hard work ethic to training 1:25:44 Tito Ortiz moving out of California 1:27:54 Reaching out for money to pay for attorney 1:34:05 Tito Ortiz blackballed from the UFC 1:36:44 Confronted over stollen golf clubs 1:44:50 Tito Ortiz caught stealing a bike 1:49:51 using Tank Abbotts influence to get back in the UFC1:51:08 interactions with Tito Ortiz's mom 1:52:52 thoughts on fighter taking steroids 1:55:43 John McCartny upset when people response 2:00:22 clearing up some statements 2:08:33 Tank Abbott vs John McCartny2:14:50 interview wrap up/ outro#TankAbbott #TitoOrtiz #MMAHistoryPodcast #UFC

His work has been captured in an award-winning series called The Last Dolphin Hunters, which opens tomorrow in Auckland.

Cindy Abbott Letro on making movies in Buffalo full 403 Mon, 22 Jun 2026 08:15:00 +0000 rIvGYMz4TKSL6Jb8Xf1mJ4Y5YVTjUUbz news WBEN Extras news Cindy Abbott Letro on making movies in Buffalo Archive of various reports and news events 2024 © 2021 Audacy, Inc. News https://player.amperwavepodcasting.com?feed-link

Craig and Cory discuss the big win for the Reds. They covered the Reds offensive explosion for a 10-2 win over the New York Yankees powered by Sal Stewart's 6 RBI, Edwin Arroyo's four-hit day, a big offensive breakout, and another strong performance from Andrew Abbott. Craig then covers the minors and Sunday's series finale with the Yankees. ------------------------------------ Check out our partners ⤵️   Book your appointment at Richter & Phillips today: https://richterphillips.com/pages/chatterbox-sports    Apply today at Sharefax Credit Union: Sharefax.org or call 513-753-2440   The Anthony Muñoz 78 Cigar! Get your box today: https://www.anthonymunoz.com/anthony-munoz-78-cigars    It's OK not to be OK! Need Help? Call or text 988 DAY OR NIGHT or visit mantherapy.org   Get 20% off sitewide at Homage with promo code CHATTER at checkout: homage.com/CBOX  -----------------------------------

This sermon on Psalm 96 explains that God is the true King who deserves worship from all people everywhere. The speaker highlights four main messages from the psalm: God's salvation is for every nation, God has no rivals and stands above all other things people may worship, God alone deserves our loyalty and devotion, and God will one day return to judge the world and make everything right. The sermon encourages believers to praise God not only when life is going well but also during difficult times, because worship helps refocus their perspective on God's greatness. It also challenges Christians to share the message of Jesus with others, especially people who have never heard it, to reject modern-day idols such as wealth, success, and comfort, and to live with hope that Jesus will return to restore all creation.

Click to Subscribe: https://bit.ly/Youtube-Subscribe-SoapDirt Young and the Restless spoilers show that Diane Jenkins (Susan Walters) plots a daring escape to free herself from the clutches of Patty's (Andrea Evans) sinister doctor. Meanwhile, Nikki Newman (Melody Thomas Scott) faces a daunting diagnosis that leaves her terrified. Victor Newman (Eric Braeden) is blindsided by a secret revelation, while Jack Abbott (Peter Bergman), in his growing desperation to find his wife, takes some risky decisions.  Y&R spoilers reveal that Victor proposes that Claire Grace Newman (Hayley Erin) spearhead a new publishing division. Concurrently, Victoria Newman (Amelia Heinle) accompanies her mother, Nikki, to the doctor where they receive a distressing diagnosis - a mass on her optic nerve could lead to blindness if left untreated. Despite the risks associated with surgery and her Multiple Sclerosis, Nikki is advised to act promptly.  The Young and the Restless spoilers indicate that while Nikki grapples with her health crisis, Diane attempts to crack Patty's doctor's phone passcode. Frustrated by her confinement, she requests to join the doctor outdoors, only to be redirected to the gym downstairs. Diane's clever manipulation of the doctor hints at her impending escape. Y&R spoilers hint that Jack dealing with Patty's erratic behavior and threats to Diane's safety. In his desperation to locate Diane, Jack instructs his son, Kyle Abbott (Michael Mealor), to tail the doctor when he leaves.  More Young and the Restless weekly spoilers confirm that Nikki, fearful of losing her sight and not wanting Victor's pity, insists that Victoria keep her diagnosis a secret. However, her secret doesn't remain hidden for long as Victor uncovers something surprising about Nikki's diagnosis.  And, Y&R weekly spoilers show that the Abbott family makes a risky move to rescue Diane, while Stephanie Simmons (Vivica A. Fox) recruits Nate Hastings (Sean Dominic) for a special project.  This episode was hosted by Belynda Gates-Turner for the #1 Soap Opera Channel, Soap Dirt. Visit our Young and the Restless section of Soap Dirt: https://soapdirt.com/category/young-and-the-restless/ Listen to our Podcasts: https://soapdirt.podbean.com/ And Check out our always up-to-date Young and the Restless Spoilers page at: https://soapdirt.com/young-and-the-restless-spoilers/ Check Out our Social Media... Twitter: https://twitter.com/SoapDirtTV Facebook: https://www.facebook.com/SoapDirt Pinterest: https://www.pinterest.com/soapdirt/ TikTok: https://www.tiktok.com/@soapdirt Instagram: https://www.instagram.com/soapdirt/

Turning activewear into technology that actually supports how you move — that's the magic

lick to Subscribe: https://bit.ly/Youtube-Subscribe-SoapDirt Young and the Restless spoilers reveal unexpected romance, heartrending reunions, and surprising couple swaps in upcoming episodes. Central to the drama are characters Kyle Abbott (Michael Mealor) and Victoria Newman (Amelia Heinle), who seem primed for a fiery romance that could ignite a family feud. Notable characters like Phyllis Summers (Michelle Stafford) are also expected to make unconventional romantic choices, heightening the intrigue.  Y&R head writer Josh Griffith is known for creating and discarding romantic pairings, and we see this trend continue with the likes of Nick Newman (Joshua Morrow) and Sharon Newman (Sharon Case) whose romance appears to be stalling. Similarly, Victoria Newman's connection with Nate Hastings (Sean Dominic) seems to have lost its spark. Spoilers for Young and Restless suggest the real drama comes from the potential pairing of Kyle Abbott and Victoria Newman, which could result in a modern-day Romeo and Juliet saga set against the backdrop of the infamous Abbott vs Newman feud. This contentious romance could be further complicated considering Victoria's past marriage and children with Kyle's uncle, Billy Abbott (Jason Thompson), and Kyle's former romance with Victoria's daughter, Claire Grace Newman (Hayley Erin). More Y&R spoilers indicate that Nate Hastings, who hasn't been seen with Victoria for a while, might find himself attracted to Audra Charles (Zuleyka Silver), despite her past indiscretions. Audra's chemistry with Nate is palpable, and fans are eager to see her in a committed relationship again. Young and the Restless spoilers hint that for Victor Newman (Eric Braeden) and Nikki Newman (Melody Thomas Scott), their reconciliation seems imminent due to Nikki's deteriorating health. Lily Winters (Christel Khalil) and Cane Ashby (Billy Flynn) are also moving towards a reunion, much to the chagrin of certain characters. Lastly, Phyllis Summers may shock viewers as she develops a strange bond with Matt Clark, despite his unsavory past.   The Soap Dirt podcast has made the Top 100 List for Apple Podcasts in the Entertainment News Category. Visit our Young and the Restless section of Soap Dirt: https://soapdirt.com/category/young-and-the-restless/ Listen to our Podcasts: https://soapdirt.podbean.com/ And Check out our always up-to-date Young and the Restless Spoilers page at: https://soapdirt.com/young-and-the-restless-spoilers/ Check Out our Social Media... Twitter: https://twitter.com/SoapDirtTV Facebook: https://www.facebook.com/SoapDirt Pinterest: https://www.pinterest.com/soapdirt/ TikTok: https://www.tiktok.com/@soapdirt Instagram: https://www.instagram.com/soapdirt/

In this episode, The Thoughtful Counselor welcomes Dr. Dena Abbott to discuss their newest edited work,Culturally Responsive Mental Health Practice with Nonreligious Clients. Dr. Abbott and contributing host Dr. Theo Burnes discuss the unique barriers for non religious clients. Topics addressed include tips and strategies for counselors working with non religious clients. Drs. Abbott and Burnes also speak about the writing and publication process for authors interested in mental health topics. For more on our guests, links from the conversation, and APA citation for this episode visit https://concept.paloaltou.edu/resources/the-thoughtful-counselor-podcast  The Thoughtful Counselor is created in partnership with Palo Alto University's Division of Continuing & Professional Studies. Learn more at concept.paloaltou.edu  

In this episode of The Lead, host Christopher Kowalewski, MD, is joined by John M. Mandrola, MD, and Nassir F. Marrouche, MD, FHRS, to discuss the journal article, The Association Between Atrial Fibrillation Burden and Quality of Life: A Substudy of the SHAM-PVI Trial. Together, they explore the relationship between atrial fibrillation burden and quality of life, reviewing findings from this substudy of the SHAM-PVI Trial and discussing their relevance to patient-centered outcomes. Learning Objectives Review the key findings from the SHAM-PVI Trial substudy examining the association between atrial fibrillation burden and quality of life. Discuss the relationship between atrial fibrillation burden and patient-reported quality-of-life outcomes. Explore the implications of assessing both arrhythmia burden and quality of life when evaluating treatment outcomes in atrial fibrillation.   Host: Christopher Kowalewski, MD Guests: John M. Mandrola, MD and Nassir F. Marrouche, MD, FHRS   Disclosures: Christopher Kowalewski, MD No relevant disclosures   John M. Mandrola, MD No relevant disclosures   Nassir F. Marrouche, MD, FHRS •       Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Biosense Webster, Inc., Boston Scientific, AtriCure, Inc., Abbott, Sanofi •       Research: Abbott, Biosense Webster, Inc., Medtronic, Siemens, General Electric, Boston Scientific, Sanofi, Samsung

Practicing Love from Just Outside the Inner Ring (6.14.2026, Maddie Abbott) by River NYC Sermons

Click to Subscribe: https://bit.ly/Youtube-Subscribe-SoapDirt   Young and the Restless spoilers for June 22-26, 2026 are brewing with drama as Nikki Newman (Melody Thomas Scott)'s health deteriorates and Diane Jenkins (Susan Walters) is held captive in a gripping storyline. Meanwhile, Sally Spectra (Courtney Hope) and Billy Abbott (Jason Thompson) face challenges with their wedding venue, Devon Winters (Bryton James) confronts Cane Ashby (Daniel Goddard), and Jack Abbott (Peter Bergman) makes a bold move to save Diane.    Y&R spoilers suggest that Nikki Newman is set for a terrifying health scare in the coming week. As her condition worsens, she confronts Lily Winters (Christel Khalil) about her deal with Victor Newman (Eric Braeden) and the appointment of Cane Ashby as CEO of Chancellor. Despite the escalating tension, Lily stands by her decision, believing Cane deserves a second chance.  Diane Jenkins finds herself in a perilous situation as she is held captive by Doctor Markham. In a desperate attempt to escape, Diane discovers a cell phone but is hindered by the need for a password.    Spoilers for Young and Restless reveal Billy Abbott and his fiancée Sally Spectra face a setback in their wedding plans when their venue becomes unavailable. Sally suggests the Abbott mansion as an alternative, but Billy reveals that Diane is missing, and Patty Williams (Stacy Haiduk) has moved in, forcing Jack to evict the other residents.   More Y&R spoilers  see Devon Winters confronts Cane Ashby about his disappointing track record with Lily and their children. However, Lily intervenes, stating her belief in Cane and his potential as the new CEO.  Jack Abbott makes a difficult decision to evict his family from the Abbott mansion in a bid to save Diane. Patty Williams moves in, creating an uncomfortable living situation for Jack the week of 6/22-6/26/2026.   This episode was hosted by Belynda Gates-Turner for the #1 Soap Opera Channel, Soap Dirt.   Visit our Young and the Restless section of Soap Dirt: https://soapdirt.com/category/young-and-the-restless/  Listen to our Podcasts: https://soapdirt.podbean.com/   And Check out our always up-to-date Young and the Restless Spoilers page at: https://soapdirt.com/young-and-the-restless-spoilers/   Check Out our Social Media...  Twitter: https://twitter.com/SoapDirtTV  Facebook: https://www.facebook.com/SoapDirt  Pinterest: https://www.pinterest.com/soapdirt/  TikTok: https://www.tiktok.com/@soapdirt  Instagram: https://www.instagram.com/soapdirt/

Are you living in the season God has you in?Today, Natalie Abbott and Vera Schmitz talk about Ecclesiastes 3:1 and the temptation to live in the past or for the future instead of receiving the present season from the Lord. Together, they reflect on nostalgia, discontentment, future hopes, and the deeper longing we all have for eternity with Jesus.This Month's Memory Verse:"There is a time for everything, and a season for every activity under the heavens."

On the afternoon of August 11, 2019, customers at a popular pub in Widnes watched as landlord Christian Thornton confronted a man he had recently barred from the premises. For Chris, it was part of the job. As the long-serving landlord of the Hammer and Pincers, he had spent years looking after customers, serving pints, organising charity events, and helping make his pub a cornerstone of the local community. But what began as a routine confrontation would end in a shocking act of violence that devastated his family and sent shockwaves through Cheshire and beyond.Known affectionately as "Tigger", Chris was a devoted husband to Pam, a father of three young children, and one of the most recognisable faces in Widnes. Friends described him as kind, funny and always willing to help others. Whether he was supporting local musicians, raising money for charity, serving a cold beer to regulars or cheering on his children's sporting achievements, Chris was a man who put people first. His murder left not only a grieving family, but an entire town struggling to come to terms with the loss of a man who meant so much to so many.In this episode of British Murders with Stuart Blues, we examine the murder of Christian Thornton, the events that led to his fatal confrontation with Lee Abbott, and the investigation that followed. We explore the background tensions between the two men, the warnings and threats made in the days before the attack, the police investigation, Abbott's arrest, trial and conviction for murder, and the remarkable community response that saw hundreds rally around Chris's family. We also look at the wider concerns surrounding knife crime, pub safety, and violence in Britain's towns and cities. This is the story of a respected pub landlord, a senseless act of violence, and a community determined that Christian "Tigger" Thornton would never be forgotten.Exclusive content:Patreon - Ad Free, Early Access, Exclusive EpisodesFollow the show:British Murders with Stuart BluesDisclaimer:The case discussed in this podcast episode is real and represents the worst day in many people's lives. I aim to cover such stories with a victim-focused approach, using information from publicly available sources. While I strive for accuracy, some details may vary depending on the sources used. Due to the nature of the content, listener discretion is advised. Thank you for your understanding and support. Hosted on Acast. See acast.com/privacy for more information.

Click to Subscribe: https://bit.ly/Youtube-Subscribe-SoapDirt Young and the Restless exposes that Patty Williams (Andrea Evans) has taken extreme measures to keep Diane Jenkins (Susan Walters) captive, with the help of her former psychiatrist, Dr. Markham. The sinister plot is an attempt for Patty to win Jack Abbott's (Peter Bergman) heart. However, Jack, understanding the danger Diane is in, has to play along with Patty's demands to ensure her safety.  Y&R spoilers suggest that Victor Newman (Eric Braeden), a long-time rival of Jack, may be the financial power behind Patty's malicious plan. Victor has a history of despising Jack and may be using this opportunity to further disrupt Jack and Diane's marriage, a theory supported by a recent interview with Eric Braden.  Spoilers for Young and Restless indicate that to protect Diane, Jack confides in his son Kyle Abbott (Michael Mealor) and sister Traci Abbott (Beth Maitland) about his plan to mislead Patty. This includes a public display of affection at Society, a local hangout, which appalls Abby Newman (Melissa Ordway). Jack explains the situation to Abby, who is initially disgusted by the sight of Patty due to her past actions.  More Y&R spoilers divulge that Patty's demands escalate as she insists on moving into the Abbott mansion, forcing other family members to leave. Jack complies to maintain the ruse. Viewers question Dr. Markham's ethics as he supports Patty's delusions for financial gain. Victor Newman's involvement is further hinted at when Diane fails to meet a supposed partner in crime, as promised by a spoiler. It is speculated that Victor may be financing Patty's plot to sabotage Jack's life. The Soap Dirt podcast made the Top 100 List for Apple Podcast's Entertainment News Category. Visit our Young and the Restless section of Soap Dirt: https://soapdirt.com/category/young-and-the-restless/ Listen to our Podcasts: https://soapdirt.podbean.com/ And Check out our always up-to-date Young and the Restless Spoilers page at: https://soapdirt.com/young-and-the-restless-spoilers/ Check Out our Social Media... Twitter: https://twitter.com/SoapDirtTV Facebook: https://www.facebook.com/SoapDirt Pinterest: https://www.pinterest.com/soapdirt/ TikTok: https://www.tiktok.com/@soapdirt Instagram: https://www.instagram.com/soapdirt/

It's In The News - a look at the top diabetes stories and headlines happening now!   Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: fall Detroit and Seattle.   Okay.. our top story this week: XX The FDA approved Tzield for use in stage 3 T1D – that's what we used to just call type 1. It's the stage where the body can no longer produce enough insulin on its own to manage blood sugars you need to start insulin. This approval is for kids ages 8-17 within 8 weeks of a stage 3 T1D diagnosis. It comes after the PROTECT trial and it's the first approval of a disease-modifying therapy for stage 3 T1D. https://www.prnewswire.com/news-releases/breakthrough-t1d-celebrates-approval-of-tzield-for-use-in-stage-3-type-1-diabetes-in-the-us-302799532.html XX Encouraging results from a small study of islet cell transplantation in people with type 1 where now all 12 participants in the trial are currently living without external insulin after receiving transplanted insulin-producing islet cells.   The study, led by researchers at the University of Chicago, tested an experimental immune therapy called tegoprubart Te-GO-Proo-Bart. The drug is designed to prevent the body from rejecting transplanted cells while avoiding some of the side effects associated with standard anti-rejection medications. You've probably heard about this as the Eledon study – many of the participants have been very active on social media. It was presented at ADA. transplants.https://www.breakthrought1d.org/news-and-updates/tegoprubart-islet-transplant-all-participants-off-external-insulin/ XX New data suggest that acmopatide (ack-MOW-puh-tyd) (CT-868), an experimental once-daily dual GLP-1/GIP receptor agonist, may help people with type 1 diabetes improve blood sugar control, lose weight, and reduce insulin use. Across all doses, participants lost up to 7% of their body weight and reduced insulin use by as much as 15%. The study lasted just 16 weeks, so researchers say longer-term data will be needed to determine whether the benefits can be maintained and whether lower insulin requirements can be achieved without increasing the risk of hypoglycemia. XX A new combination therapy that pairs an amylin analog with semaglutide improved both blood sugar levels and weight loss in several groups of people with type 2 diabetes. The once-weekly injectable, known as CagriSema (KAG-ruh-SEM-uh), was evaluated in three Phase 3 REIMAGINE studies. In people early in the course of type 2 diabetes, researchers reported A1C reductions of up to 1.8 percentage points and significant weight loss compared to placebo after 40 weeks of treatment. Investigators also noted improvements in several cardiometabolic risk factors, including blood pressure. https://www.medpagetoday.com/meetingcoverage/ada/121658 XX Stelo for kids is now FDA cleared.. the over the counter Glucose Biosensor System is now approved for children as young as 2 years old who do not use insulin. The FDA identified pediatric prediabetes as a growing public health concern motivating the expanded indication, noting OTC CGMs can help younger users and their caregivers build glycemic awareness, track patterns in response to me https://www.hcplive.com/view/fda-clears-first-otc-glucose-monitor-for-children XX Insulet presented new data from its STRIVE and EVOLUTION 3 studies showing improved glucose control with its next-generation Omnipod 6. That's , the company's upcoming hybrid closed-loop system for people with type 1 and type 2 diabetes. The main difference between the Omnipod 6 and Insulet's current Omnipod 5 patch pumps is that the new system has a lower glucose target of 100 mg/dL and better Bluetooth connectivity Insulet also shared progress on a fully closed-loop system designed specifically for type 2 diabetes. It  does not require carb-counting or insulin bolusing ahead of meals. Physicians also don't need to program the starting settings.   XX Abbott shared new research highlighting challenges in identifying and managing diabetic ketoacidosis (DKA). The studies coincide with the company's development of Libre Duo, a dual glucose-ketone sensor that continuously tracks both measurements. Abbott reported that DKA can be difficult to recognize when patients first arrive at the hospital, based on data from more than 100,000 people. The company has submitted the dual sensor to the FDA and recently received CE Mark approval in Europe. More news from ADA including info from Dexcom, Sequel, Sensonics and the world loses a tireless T1D advocate.. that's all to come right after this. --   Back to the news.. XX   Dexcom announced its acquisition of Nutrisense, a company that combines continuous glucose monitoring with nutrition coaching and behavioral support. At ADA, the company also presented results from the CONNECT study showing significant A1C reductions and improved glucose control in people with type 2 diabetes not using insulin. The findings add to growing evidence supporting CGM use beyond intensive insulin therapy. We did an episode with CEO Jake Leach at ADA about these announcements as well as updates on G8, their hospital product and much more. XX Sequel Med Tech reported positive clinical results evaluating its twiist automated insulin delivery system in people with type 2 diabetes. The study showed improvements in A1C and time in range over 13 weeks XX Senseonics presented new real-world data supporting the performance of its Eversense 365 implantable CGM. The analysis included more than 12,000 sensors and demonstrated sustained accuracy and effectiveness in both open-loop and automated insulin delivery settings. Researchers also evaluated Eversense use with Sequel Med Tech's twiist system. The findings support broader use of long-term implantable CGM technology.   -- MiniMed used ADA 2026 to spotlight two recently cleared diabetes management systems. The MiniMed Flex pump offers a smaller, smartphone-controlled insulin pump option, while MiniMed Go combines the InPen smart insulin pen with Abbott's Instinct sensor. The products received FDA clearance earlier this year. XX Tandem Diabetes Care highlighted data supporting the use of its Control-IQ automated insulin delivery technology during pregnancy. Results from the CIRCUIT trial showed users spent approximately three additional hours per day in the recommended pregnancy glucose range compared with standard therapy. The findings helped support recent regulatory approvals for pregnancy use in both Europe and the United States. Tandem also expanded indications for adults with type 2 diabetes. XX Beta Bionics presented real-world data from the first three years of iLet Bionic Pancreas use. The company reported a 25% improvement in time in range among users, along with positive feedback from clinicians about simplified diabetes management. The iLet system requires only a user's weight to begin therapy and eliminates carbohydrate counting. Beta Bionics also highlighted growing access to near-real-time outcomes through its public data dashboard. XX MannKind presented new findings supporting its Afrezza inhaled insulin at ADA 2026. A post-hoc analysis of the INHALE-1 study found that pediatric users reported greater treatment satisfaction compared with those using rapid-acting injected insulin. The results come shortly after FDA approval expanded Afrezza's indication to include children. We did a bonus episode with one of the lead investigators of the study that lead to that approval. XX Adaptyx presented early clinical data supporting a wearable sensor that continuously measures cortisol levels. The device successfully tracked cortisol changes during both controlled testing and overnight monitoring in first-in-human studies. Company leaders say cortisol plays a major role in conditions including diabetes, hypertension, and depression. The technology uses synthetic DNA-based molecular switches to generate real-time readings.   XX Biolinq shared new clinical findings for its Shine continuous glucose monitoring system. The needle-free device combines glucose monitoring with activity and sleep tracking .The system received FDA clearance in 2025. They're also looking at measuring lactate through the sensor. XX Long-time T1D advocate Kent Schnakenberg died last week. Schnakenberg was known in his community for using his love of bicycling to raise awareness of Type 1 diabetes. He also advocated for improving the lives of those living with the disease. Inspired by his niece, Michelle, who was diagnosed with juvenile diabetes when she was 13 years old, since 2014 he has traveled around the country cycling thousands of miles, speaking to hundreds and hundreds of kids and raising Money. According to Schnakenberg's family, he suffered a head trauma incident in his home on Wednesday. I spoke to Kent years ago – I believe the first year of the podcast. A sad loss but wonderful to see so many tributes and memories posted on social media in the last few days. https://diabetes-connections.com/john-costik-co-creator-of-nightscout-team-schnak/ https://www.wibw.com/2026/06/12/team-schnak-founder-kent-schnakenberg-passes-away/ XX And finally. Alexander Zverev (ts-ver-uhv) won the French Open, his first Grand Slam title. He lives with type 1, he paused a couple of time to check his blood sugar. He was diagnosed at age 4 and partners with Medtronic. "Becoming a professional tennis player was always my dream," Zverev shared in an article posted by Medtronic. "Early on, I was told that competing at the highest level with diabetes was impossible — but my family and I refused to accept that. That's why I'm partnering with Medtronic Diabetes: I want every person with diabetes to feel empowered to live the life they want." He also has a foundation committed to children with type 1 diabetes. Among other things, the life-saving insulin and other essential drugs are provided – also in developing countries." https://www.mensjournal.com/news/alexander-zverev-diabetes-wins-french-open-2026-medical-condition

In his latest interview with Chris Steyn, Grant Abbott the General Secretary of the National Tertiary Education Union (NTEU) shares evidence collected over years for the criminal complaint lodged against Vice-Chancellor Professor Sakhela Buhlungu who was recently placed on precautionary suspension by the Council and now faces charges of gross misconduct. Allegations in the union's criminal complaint include the appointment and promotion of individuals outside lawful recruitment processes, the circumvention of governance structures, the approval of substantial financial settlements of millions of rands and remuneration adjustments without proper justification. It also sets out how the Vice Chancellor selectively used disciplinary processes to protect his allies and targeted whistleblowers. Meanwhile, some of those who benefitted from the Vice-Chancellor's “schemes” are now the accused in corruption and fraud cases. “The problem is that you can't position yourself as a corruption buster and then in the process of doing that create more corruption...”

This message is about finding peace, security, and hope in a relationship with God as our Shepherd. Using Psalm 23, the pastor explains that believers can confidently say “I will not lack, I will not fear, and I will dwell” because God provides for their needs, walks with them through life's darkest valleys, and ultimately leads them to an eternal home with Him. The sermon emphasizes that fear and hardship are real parts of life, but God's presence is greater than any difficulty. Just as a shepherd guides, protects, and cares for sheep, God lovingly leads His people, reminding them that they belong to Him ("You are mine"). The central message is that our confidence comes not from our own strength or circumstances, but from trusting the Good Shepherd who never abandons His people and promises His goodness, mercy, and eternal presence.

On this week's episode of the Unnatural Selection Podcast, we discuss: Where Australia ranks as global conflict hits levels unseen since WWII.Richard Marles 'stood up' on AUKUS trip after British counterpart John Healey's shock resignation.Abbott and Hanson's ancient feud is rife with political drama and biblical comeuppance.Cars burn in Belfast, bricks fly in Southampton – and the ubiquitous cry of ‘civil war' goes up again.Switzerland is set to vote on a population cap. Here's why it's divided the nation.Thousands rally in Albania in largest protest yet against Kushner resort.Statement on the US government directive to suspend access to Fable 5 and Mythos 5. Unnatural Selection is a deeply unqualified Australian and American political comedy podcast. Hosted by Jorge Tsipos, Adam Direen, and Tom Heath, the show attempts to make sense of the weekly news cycle through a highly unserious lens.Find more episodes and links at www.UnnaturalShow.com.Disclaimer: Unnatural Selection is a comedy podcast. The political commentary, news analysis, and general banter are for comedic purposes and should absolutely not be taken seriously.#auspol #uspol #politicalcomedy #australianpolitics #uspolitics #newsandpolitics #comedypodcastTwitter:@JorgeTsipos@UnnaturalShowInstagram:@JorgeTsipos@UnnaturalShowThreads:@tom.heath@JorgeTsipos@UnnaturalShow

Comedy: Alan Young Show 12/4/45 ABC, Abbott and Costello Show 4/5/45 NBC.

Send us Fan MailYesenia Avellaneda is an engineering leader whose career sits at the intersection of innovation, operations, and impact. Currently a Senior Project Engineer within Global Operations at Abbott, she has built a reputation for turning complex ideas into scalable, high-performing manufacturing systems. From leading New Product Introduction (NPI) efforts to executing international production transfers and launching entirely new facilities, Yesenia thrives where strategy meets execution. Her work has had measurable impact. She has led capital projects exceeding $5 million, driven production efficiency improvements, and implemented Lean manufacturing and Six Sigma methodologies to enhance quality and throughput. In one role, she helped boost line productivity by 200%, all while overseeing teams of 60+ personnel and ensuring compliance with rigorous FDA and regulatory standards . Her ability to align cross-functional teams—from product development to operations—has made her a key driver of successful product launches and operational excellence. Yesenia's academic foundation reflects her human-centered approach to engineering. She earned her bachelor's degree in Human Physiology from the University of Oregon and later completed a master's in Biomedical Engineering from the University of Portland. This unique combination allows her to bridge the gap between clinical needs and engineering solutions—an essential skill in the medical device industry. Beyond her technical and leadership accomplishments, Yesenia is deeply committed to giving back. As Regional Vice President for SHPE Region 6 and a longtime advocate for underrepresented communities in STEM, she actively works to create inclusive pathways for future engineers. She's also an experienced speaker, sharing insights on leadership, career growth, and navigating STEM as a first-generation professional. In this conversation, Yesenia brings a rare perspective—one that combines hands-on engineering, large-scale operational leadership, and a mission-driven approach to making a broader impact in both industry and community. LINKS: Yesenia Avellaneda LinkedIn: https://www.linkedin.com/in/yesenia-avellaneda/ https://shpe.org/ Aaron Moncur, host  Subscribe to the show to get notified so you don't miss new episodes every Friday.The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment like cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us at www.teampipeline.usWatch the show on YouTube: www.youtube.com/@TeamPipelineus 

Choice Classic Radio presents Suspense, featuring today's episode titled “The Escape of Lacey Abbott.” Please consider supporting our show by becoming a patron at http://choiceclassicradio.com We hope you enjoy the show!

Teaching Shakespeare's Theatre of the World (Cambridge University Press, 2025) engages with one of Shakespeare's greatest thought-experiments: How does one navigate the 'theatre of the world'? It invites students to examine how Shakespeare challenges this metaphor's vertical hierarchies in response to shifting understandings of cosmological order. Teachers will find rich contextual frameworks for exploring how Shakespeare envisions 'worlds' as emerging from dynamic variables, raising urgent questions about how identity and justice are environmentally constructed. Focal plays include A Midsummer Night's Dream, As You Like It, Hamlet, Henry V, The Merchant of Venice, and Othello. Each discussion features student centered 'Explorations'. These play-specific classroom activities can also be adapted across Shakespeare's corpus and tailored for both secondary and university-level students. These exercises encourage non-linear critical and creative thinking, inviting students to contemplate big ideas and generate new perspectives about the shared points of contact between Shakespeare's world and their own. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

On this Salcedo Storm Podcast:Brandon Waltens, is a Senior Editor at Texas Scorecard. He is the host of the essential Daily Headlines at Texas Scorecard.

The Texas Republican Party faces today a seeming no-brainer choice: Will it stand with the man at the top of the GOP ticket this fall, Governor Greg Abbott, and 1.9 million voters in its base in opposing sharia-supremacism?  Or, will it legitimize among its convention delegates operatives of the Muslim Brotherhood and its pitbull front, the Council on American-Islamic Relations (CAIR) – which Mr. Abbott has properly designated as terrorist organizations. One of them, Dr. Tarek Hussein, actually founded CAIR's Texas chapter and authored a paper about how to infiltrate political parties. The obvious purpose of doing so is to advance the Brotherhood's stated “mission” of “destroying Western civilization from within with the help of unbelievers.” Banning sharia is a winning issue for Republican and other patriots – unless the Texas GOP submits to it, alienating them and further empowering and emboldening the jihadists.  This is Frank Gaffney.

Teaching Shakespeare's Theatre of the World (Cambridge University Press, 2025) engages with one of Shakespeare's greatest thought-experiments: How does one navigate the 'theatre of the world'? It invites students to examine how Shakespeare challenges this metaphor's vertical hierarchies in response to shifting understandings of cosmological order. Teachers will find rich contextual frameworks for exploring how Shakespeare envisions 'worlds' as emerging from dynamic variables, raising urgent questions about how identity and justice are environmentally constructed. Focal plays include A Midsummer Night's Dream, As You Like It, Hamlet, Henry V, The Merchant of Venice, and Othello. Each discussion features student centered 'Explorations'. These play-specific classroom activities can also be adapted across Shakespeare's corpus and tailored for both secondary and university-level students. These exercises encourage non-linear critical and creative thinking, inviting students to contemplate big ideas and generate new perspectives about the shared points of contact between Shakespeare's world and their own. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literary-studies

On Episode 33 of Season 6 of the Old Radio Comedy Podcast,we bring you the May 11, 1944 episode from the Abbott and Costello Show, “Job at a Department Store” with guest Claire Trevor. As always, each episode has been remastered and optimized for you. Enjoy! Be sure to check out our YouTube channel, An Evening of OldTime Radio:https://www.youtube.com/@aneveningofoldtimeradio

Teaching Shakespeare's Theatre of the World (Cambridge University Press, 2025) engages with one of Shakespeare's greatest thought-experiments: How does one navigate the 'theatre of the world'? It invites students to examine how Shakespeare challenges this metaphor's vertical hierarchies in response to shifting understandings of cosmological order. Teachers will find rich contextual frameworks for exploring how Shakespeare envisions 'worlds' as emerging from dynamic variables, raising urgent questions about how identity and justice are environmentally constructed. Focal plays include A Midsummer Night's Dream, As You Like It, Hamlet, Henry V, The Merchant of Venice, and Othello. Each discussion features student centered 'Explorations'. These play-specific classroom activities can also be adapted across Shakespeare's corpus and tailored for both secondary and university-level students. These exercises encourage non-linear critical and creative thinking, inviting students to contemplate big ideas and generate new perspectives about the shared points of contact between Shakespeare's world and their own. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/performing-arts

Teaching Shakespeare's Theatre of the World (Cambridge University Press, 2025) engages with one of Shakespeare's greatest thought-experiments: How does one navigate the 'theatre of the world'? It invites students to examine how Shakespeare challenges this metaphor's vertical hierarchies in response to shifting understandings of cosmological order. Teachers will find rich contextual frameworks for exploring how Shakespeare envisions 'worlds' as emerging from dynamic variables, raising urgent questions about how identity and justice are environmentally constructed. Focal plays include A Midsummer Night's Dream, As You Like It, Hamlet, Henry V, The Merchant of Venice, and Othello. Each discussion features student centered 'Explorations'. These play-specific classroom activities can also be adapted across Shakespeare's corpus and tailored for both secondary and university-level students. These exercises encourage non-linear critical and creative thinking, inviting students to contemplate big ideas and generate new perspectives about the shared points of contact between Shakespeare's world and their own. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/education

Teaching Shakespeare's Theatre of the World (Cambridge University Press, 2025) engages with one of Shakespeare's greatest thought-experiments: How does one navigate the 'theatre of the world'? It invites students to examine how Shakespeare challenges this metaphor's vertical hierarchies in response to shifting understandings of cosmological order. Teachers will find rich contextual frameworks for exploring how Shakespeare envisions 'worlds' as emerging from dynamic variables, raising urgent questions about how identity and justice are environmentally constructed. Focal plays include A Midsummer Night's Dream, As You Like It, Hamlet, Henry V, The Merchant of Venice, and Othello. Each discussion features student centered 'Explorations'. These play-specific classroom activities can also be adapted across Shakespeare's corpus and tailored for both secondary and university-level students. These exercises encourage non-linear critical and creative thinking, inviting students to contemplate big ideas and generate new perspectives about the shared points of contact between Shakespeare's world and their own.

Sunset for the days of Texas as the wild west of AI? A closer look at the Gov. Greg Abbott's new plan for greater oversight of the rapidly expanding landscape of data centers statewide.Day one of the World Cup — do the numbers add up? A closer look at projections about the economic impact here […] The post Gov. Abbott calls for new oversight on Texas data centers appeared first on KUT & KUTX Studios -- Podcasts.

Sponsored By:→ Neuro | Go to ⁠https://getneuro.com⁠ and use code ONEDAY at checkout for 15% OFF your entire order.Every single grocery store aisle has been disrupted by better-for-you brands. Every one — except the aisle where the fastest-growing demographic in America shops for nutrition.Jon Bier sits down with Jess Haghani — founder and CEO of Lucille Health — for a conversation about what happens when you spot a gap so obvious it feels impossible that no one has filled it yet. Jess watched her grandmother, Lucille, come home from heart surgery and get handed the same ultra-processed nutrition shakes that haven't meaningfully changed since the 1970s. Products people hide in their basements. Products they're embarrassed to let their grandkids see. A $6 billion category with zero dignity, zero innovation, and no real competition.So she left KKR, went to Harvard Business School, and built the brand she knew had to exist.This episode is a little different. Jess hasn't built a nine-figure business yet. But Jon believes she will and this conversation is why.In this episode:• Why less than 1% of food and beverage innovation is happening for older adults, despite them being the fastest-growing consumer demographic in the world — and why that gap is finally closing• The real story behind Lucille: how watching her 92-year-old grandmother hide a nutrition shake in her basement became the founding moment of a brand built around dignity• What it looks like to take on Abbott and Nestlé with no money, no formulation experience, and no playbook and why that might actually be the advantageFind Jess & Lucille:• Jess on Instagram: https://www.instagram.com/jesshaghani/• Lucille Health: https://www.lucillehealth.com• Lucille on Instagram: https://www.instagram.com/lucillehealth/Timestamps:0:00 - Intro1:21 - Jon's personal experience with his dad's hospital nutrition2:04 - Why do hospitals still serve such poor nutrition products?7:43 - The corruption of big incumbents like Abbott and Nestle9:59 - How big is the older adult nutrition market?11:01 - Why has this category never been disrupted?11:38 - The shame and stigma around products like Ensure and Boost15:25 - Jess's background: London, real estate, KKR, HBS17:02 - The story of Lucille, Jess's 92-year-old grandmother19:51 - Assembling the team and figuring it out step by step25:00 - Should founders pay themselves a salary?31:04 - The broader vision: beyond beverages, full category disruption37:23 - The 70+ demographic has the highest retention rate43:18 - Jon's confidence in Lucille Health's future

In this episode of The Lead, host Christopher C. Cheung, MD, MPH, FHRS, is joined by Edward P. Gerstenfeld, MD, MS, FHRS, and Paul C. Zei, MD, PhD, FHRS, to discuss the journal article, A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD). Together, they review the study design and findings, examining pulsed field ablation and anti-arrhythmic drug therapy as first-line treatment approaches for patients with persistent atrial fibrillation. Learning Objectives Review the design and key findings of the AVANT GUARD study comparing pulsed field ablation with anti-arrhythmic drug therapy as first-line treatment for persistent atrial fibrillation. Discuss the potential role of pulsed field ablation as an initial treatment strategy for patients with persistent atrial fibrillation. Examine the comparative considerations of ablation-based and pharmacologic approaches in the management of persistent atrial fibrillation.   Podcast Contributors: Host: Christopher C Cheung, MD, MPH, FHRS       Guests: Edward P. Gerstenfeld, MD, MS, FHRS and Paul C Zei, MD, PhD, FHRS   Disclosures: Christopher C Cheung, MD, MPH, FHRS Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biotronik, Biosense Webster, Inc., Abbott Edward P. Gerstenfeld, MD, MS, FHRS Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biosense Webster, Inc., Abbott, Boston Scientific, Varian Medical Systems Other Non-Financial Relationships: Adagio Medical, Boston Scientific, Abbott Medical Research: Abbott Medical Officer, Trustee, Director, Committee Chair, or Other Fiduciary Role: American College of Cardiology Paul C Zei, MD, PhD, FHRS Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Varian Medical Systems, Biosense Webster, Inc., Abbott, Boston Scientific, APT Medical Research: Biosense Webster, Inc.

Host: Wilfried Mullens Guest: Stephan Baldus Want to watch that extended interview, go to: https://esc365.escardio.org/event/2560?resource=interview Want to watch that entire episode? Go to: https://esc365.escardio.org/event/2560   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Transcatheter treatment of tricuspid regurgitation Carcinoid heart disease Milestones: MADIT-II Trial Host: Wilfried Mullens Guests: Stephan Baldus, Heidi Connolly and Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2560 Want to watch that extended interview on transcatheter treatment of tricuspid regurgitation, go to: https://esc365.escardio.org/event/2560?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Heidi Connolly, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Have you Been To? Been to? Bin Two? Been To? Have you Bin Two Bin Two? Abbott & Costello continue ad infinitum   We ask, where has Mike Boyne Bin Two. Where is he now? And just how long has he wanted to be a slug balancer?   Yes, Friend Of The Pod and Industry Legend Mike Boyne rejoins us in TM&TM Towers to share thoughts on the trade, running and indie, staffing, wine selection, and showing off his huge guns.   So pour a brandy, grab a fruit rollup, and let's talk about the industry.

We're taking the summer off and rebroadcasting some of our favorite episodes in the archives over the next few months. First up is our 2017 conversation with Pentagram partner Abbott Miller! We'll be back with new episodes in September! — Abbott Miller is a designer, writer, and a partner at Pentagram where he leads a team designing identities, exhibitions, and books. Before Pentagram, Abbott ran a studio, Design Writing Research, with Ellen Lupton and wrote for publications like Eye, Print, and I.D. A monograph of his design and writing, called Design and Content, was published in 2014. In this conversation, Abbott and I talk about where his interest in critical theory came from and how he's worked to incorporate it into his design work, using writing to find new ways into design, and how his various interests have come together in his current work designing exhibitions at Pentagram. Links from this episode can be found at: https://scratchingthesurface.fm/post/161266191870/30-abbott-miller — We're continuing to publish new content on our Substack. Paid subscribers get bonus interviews every month. Sign up and support the show here: surfacepodcast.substack.com

Daniel Norcross and Jeremy Coney bring you Oval and Out - your bitesize look as Surrey return to four-day cricket at the Kia Oval. After a rain affected second day left Surrey needing something special to force a result, some regard resistence from Potgieter and Abbott looks to have all but secured a draw for the visitors.

El episodio 119 llegó con framework, números y oportunidades que no te podés perder.Arrancamos con lo más accionable del episodio: los 7 principios de Y Combinator para construir una empresa en la era AI. No es AI como herramienta, es AI como sistema operativo de toda la organización. Loops cerrados en cada proceso, empresas legibles para los modelos, fábricas de software donde los humanos definen los specs y la AI construye el código, y equipos lo más flat posible donde cada persona tiene una responsabilidad directa y no hay lugar para esconderse. Si estás construyendo algo hoy, este es el episodio.Después el número que más sorprendió de la semana: Uber gastó 500 millones de dólares en tokens en tres meses y su CFO admitió públicamente que no vio ningún resultado. La contracara fascinante es que los propios modelos de AI no saben cuánto les cuesta producir cada token. Están vendiendo algo a un precio que ellos mismos no entienden todavía. Y mientras tanto, la mayoría de las empresas está descubriendo que un modelo open source más chico instalado en sus propios servidores les da el 90% del resultado al 2% del costo.También hablamos de la nueva métrica que define esta era: el EBITDA ya tiene una T nueva. Ya no es solo Before Interest, Taxes, Depreciation and Amortization. Ahora es Before Tokens también. Si tu empresa no está midiendo cuánto gasta en tokens, no está midiendo bien.En el frente de IPOs, Anthropic hizo su filing privado, OpenAI apunta a septiembre y SpaceX está cada vez más cerca. Tres movimientos que van a redefinir el mercado en los próximos meses.Cerramos con dos temas más personales. Primero, el debate entre Oura, Whoop y Fitbit — cuál sirve, para quién y por qué el nuevo monitor de glucosa Lingo de Abbott a 30 dólares puede ser uno de los dispositivos más importantes para entender tus hábitos. Segundo, cómo filtrar el spam de family offices y brokers de secundarios que llega por LinkedIn todos los días sin perder tiempo.

Comedy on a Saturday First, a look at the events of the day.Then, The Lucky Strike Program starring Jack Benny, originally broadcast  June 6, 1954, 72 years ago, Jack Goes To Dallas.  The last show of the season. Jack is off to Dallas and the gang goes down to the airport to see him off.Followed by The Harold Peary Show, originally broadcast June 6, 1951, 75 years ago, Peabody's Sister Takes Over the Radio Station.  Stanley Peabody is leaving the radio station. His sister takes over, even though Harold thinks he should get the job. Then, The Great Gildersleeve starring Harold Peary, originally broadcast June 6, 1943, 83 years ago, The Wedding Shower.   A surprise shower for Leila. Leroy gets fired from Peavey's drug store...for punching a customer!Followed by Abbott and Costello, originally broadcast June 6, 1946, 80 years ago, Bud and Lou Need Some Dough. Lou loses his place in the script during the opening routine. Lou "needs some dough" to pay the rent. The boys are locked in their room until they can find $60, possibly by "kneading some dough."Finally, Lum and Abner, originally broadcast June 6, 1935, 91 years ago, Squire to Start Rival Theater.   Squire Skimp has threatened to open his own movie theatre since Lum and Abner won't take him in as a partner.Thanks to Debbie B. for supporting our podcast by using the Buy Me a Coffee function at http://classicradio.streamCheck out Professor Bees Digestive Aid at profbees.com and use my promo code WYATT to save 10% when you order! If you like what we do here, visit our friend Jay at http://radio.macinmind.com for great old-time radio shows 24 hours a day

Capitalizing on the success of Buck Privates, Universal Pictures wastes no time enlisting Abbott & Costello into the Navy!  The second of FOUR films starring the comedy duo in 1941 alone!  Co-starring Dick Powell and Claire Dodd.

Law and Chaos wishes a big mazal tov to Kristi Noem on her new, very real job as assistant principal of the Yeehaw American Hegemony Club. And to Lindsey Halligan on catching a Florida Bar investigation.   We'll discuss our recent post on Pam Bondi's very timely announcement that she intends to take over state bar complaints against DOJ employees. It comes at a moment when district court judges are telegraphing very clearly that they are going to start holding DHS and DOJ in criminal contempt for rampant disregard of court orders. Specifically, Judge Michael Farbiarz of the District of New Jersey says he'll require sworn affidavits from officials at the US Attorneys Office and ICE for every habeas release case that comes before him. This will likely serve as a model for other judges whose dockets are buckling under the weight of habeas cases from all the immigrants ICE is illegally detaining.   Elections expert Joe Dye is back to discuss Tuesday's primary elections in Texas, Arkansas, and North Carolina.   And for subscribers, we'll discuss the shadow docket order in which the six conservative justices leapt in to save New York Rep. Nicole Malliotakis's seat.   Lindsey Halligan Is Under Investigation by the Florida Bar https://www.nytimes.com/2026/03/05/us/politics/lindsey-halligan-investigation-florida-bar.html   Bondi Says She's The Bar Now https://www.lawandchaospod.com/p/bondi-says-shes-the-bar-now   Judge Farbiarz Order re Contempt https://storage.courtlistener.com/recap/gov.uscourts.njd.590517/gov.uscourts.njd.590517.30.0.pdf   Malliotakis v. Williams [2026 Supreme Court New York redistricting decision] https://www.supremecourt.gov/opinions/25pdf/25a914_1p24.pdf   Abbott v. LULAC [2025 Supreme Court stay of Texas map] https://www.supremecourt.gov/opinions/25pdf/25a608_7khn.pdf   Rucho v. Common Cause [2019 Supreme Court gerrymandering opinion] https://scholar.google.com/scholar_case?case=6090361490276671133   Steve Vladek, Bonus 214: Emergency Relief from State Courts [One First] https://www.stevevladeck.com/p/bonus-214-emergency-relief-from-state   Show Links: https://www.lawandchaospod.com/ BlueSky: @LawAndChaosPod Threads: @LawAndChaosPod Twitter: @LawAndChaosPod  

Allie examines the Texas Senate race between Republican Ken Paxton and Democrat James Talarico and tackles the tough question: How should Christians vote when both candidates have serious flaws? She breaks down Paxton's moral failings and past scandals alongside Talarico's radically progressive positions—including his claims that “God is non-binary,” strong support for abortion, gender transitions for minors, prison abolition, and open-border policies—while evaluating their records on life, family, borders, and justice through a biblical lens. Additionally, Allie interviews her brother, Justin Simmons, who is the US Attorney for the Western District of Texas. Justin details his mission to crack down on drug smuggling, human trafficking and fraud, while urging others to improve their communities rather than choosing a life of self-gratification. Gov. Abbott declares CAIR a terrorist organization: https://gov.texas.gov/news/post/governor-abbott-designates-muslim-brotherhood-cair-as-foreign-terrorist-organizations Ken Paxton's Impeachment: https://ballotpedia.org/Impeachment_of_Ken_Paxton,_2023 Share the Arrows 2026 is on October 10 in Dallas, Texas! Tickets are on sale now at: ⁠⁠⁠⁠⁠⁠https://sharethearrows.com⁠⁠⁠ Share the Arrows is sponsored by: A'del Natural Cosmetics: AdelNaturalCosmetics.com Range Leather: RangeLeather.com/ALLIE We Heart Nutrition: WeHeartNutrition.com Buy Allie's book "Toxic Empathy: How Progressives Exploit Christian Compassion": ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.toxicempathy.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ – Time Codes 0:00 Introduction 1:11 Can James Talarico win in Texas? 39:14 Interview with the US Attorney for West Texas 1:09:57 Closing Remarks – Today's Sponsors: We Heart Nutrition | Check out We Heart Nutrition at ⁠⁠⁠WeHeartNutrition.com⁠⁠⁠ and use the code ALLIE for 20% off. A'del | Visit AdelNaturalCosmetics.com and enter promo code ALLIE for 25% off your first-time purchase. Good Ranchers | To support a company that honors America's past, present, and future, visit ⁠GoodRanchers.com⁠ today. When you start your plan, you'll get to pick a free meat that will be included in every order for life, and you'll get $25 off your first order using my exclusive code, ALLIE. Legacybox | Visit Legacybox.com/ALLIE to take advantage of Legacybox's Spring Cleaning sale and preserve your family's story. Alliance Defending Freedom | Every dollar you give to ADF by March 31 will be doubled by a special matching grant, only while matching funds last. Go to JOINADF.com/ALLIE or text ALLIE to 83848 to have your gift matched to protect brave Americans. Episodes You May Like: Ep 1315 | James Talarico Is More Demonic Than You Think https://podcasts.apple.com/us/podcast/ep-1315-james-talarico-is-more-demonic-than-you-think/id1359249098?i=1000754075488 Ep 1305 | Is Trump Targeting Talarico? Colbert's Lie Exposed https://podcasts.apple.com/us/podcast/ep-1305-is-trump-targeting-talarico-colberts-lie-exposed/id1359249098?i=1000750390293 Ep 1221 | Rebutting 'Progressive Christian' James Talarico's Bad Theology https://podcasts.apple.com/us/podcast/ep-1221-rebutting-progressive-christian-james-talaricos/id1359249098?i=1000718715520 --- ► Buy Allie's book, "You're Not Enough (& That's Okay): Escaping the Toxic Culture of Self-Love": https://alliebethstuckey.com/book ► Subscribe to the podcast: iTunes: https://apple.co/2UVssnP Spotify: https://spoti.fi/2FwkXxj ► Connect with Allie on Social Media: https://twitter.com/conservmillen https://www.instagram.com/alliebstuckey/ https://facebook.com/allieBlazeTV/ ► Relatable merchandise – use promo code 'ALLIE10' for a discount: https://shop.blazemedia.com/collections/allie-stuckey

It's in the News! The top diabetes stories and headlines happening now. Top stories this week include: Afrezza inhaled Insulin is Approved for Kids, CGM + Ketone Monitor gets European approval, Food Coloring & Diabetes Study, Device Recalls include Omnipod and Dexcom, Beta Bionics shares more about their patch pump, ADA conference info and more! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcripts: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. ADA starts this week – safe travels to those of you heading to New Orleans. We'll be covering remotely so please follow on social – make sure to Like the FB page or join the group. We've got a wrap up episode planned for this podcast as well as some indepth interviews with the newsmakers from the conference. I will see some of you next week in Chicago. We have a couple of seats left for our Club 1921 dinner on June 10th in Northbrook – this is a FREE dinner for HCPs and patient leaders – all about screening for T1D. More info on the website under the events tab. Okay.. our top story this week: XX Afrezza inhaled insulin is now approved for kids and teens. The FDA okayed MannKind's afrezza for children 6 and older with type 1 and type 2 diabetes. MannKind says its proprietary Technosphere drug delivery platform enables the rapid absorption of insulin into systemic circulation. This follows FDA approval earlier this year for an update that revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. MannKind also completed enrollment in February for a study evaluating the initiation of Afrezza therapy shortly after type 1 diabetes diagnosis in pediatric patients.   The company said it made Afrezza available for eligible patients for $35 or less per month. Desmond Schatz, professor of pediatrics at the University of Florida College of Medicine, said: "Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary. With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option." Lots more to come on this – we're working on a bonus episode with one of the pediatric endos who worked on the clinical trials that led to this approval – hopefully have that out later this week. https://www.massdevice.com/mannkind-fda-approval-inhaled-insulin-children/ XX FDA has agreed to consider a new drug for the treatment of adults with type 1 and chronic kidney disease. Finerenone (fy-near-uh-known) is currently approved in the US for adults with CKD associated with type 2 diabetes and for adults with heart failure with left ventricular ejection fraction of 40% or greater. Chronic kidney disease (CKD) is present in over one-third of adults with diabetes, and because it's such a serious condition, interventions are needed to reduce its incidence and help people live a long and prosperous life. https://www.docwirenews.com/post/fda-grants-priority-review-to-finerenone-snda-for-type-1-diabetes-associated-ckd XX Abbot gets European approval for the world's first dual glucose‑ketone sensing technology for people with diabetes. They're calling this Libre Duo and Libre Duo 10 Day, and it's designed to continuously measure glucose and ketone levels every minute. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes   XX Huge recall for Omnipod. Insulin says a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery  with specific lots of its Omnipod 5, Dash and Eros pods. Insulet said the scope of this action reaches approximately 7 million pods. This issue is separate from the March recall that affected certain Omnipod 5 lots. According to the Acton, Massachusetts-based company, some of its affected pods may have a small tear in the tubing (cannula) just above the skin. This tear lands between the pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the device instead of being fully delivered into the body as intended. This may lead to under-delivery of the therapeutic.   Individuals using an affected pod may notice wetness on the skin or pod adhesive or detect the smell of insulin. However, some cases may prove difficult to detect and go unnoticed. Of the approximately 7 million pods included in the action, approximately 60% have been consumed or are expired. The pods affected by the correction represent approximately 8.5% of the 2025 global Omnipod pod prodcution. Insulet says it has sufficient supply to replace affected pods. It expects no disruption to product availability. The company said it has notified the FDA and all other relevant regulatory authorities of its action.   The full list of affected pod lots can be found here. https://www.massdevice.com/insulet-another-omnipod-5-recall-dash-eros/ XX Dexcom is warning that certain scrapped glucose sensors have been stolen and resold. Dexcom said it has not received any reports of severe adverse events associated with the stolen product. One lot of scrapped devices carries a risk of infection for sensors that are not properly sterilized, and another lot had an elevated internal testing failure rate, meaning users would have an increased risk of having no sensor readings available. Dexcom said the affected sensors were stolen during the destruction process and then sold by third parties. The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling.   Dexcom said it traced sales of the stolen devices to Pharmsource, which is not an authorized Dexcom distributor but supplies some independent pharmacies and U.S. durable medical equipment distributors. Because of this, pharmacies that purchase products from Pharmsource should review their inventory, Dexcom said.   People with sensors from the affected lots should not use those sensors and can call customer support to request replacements. Dexcom has set up a website to help users check if their devices are affected. https://www.medtechdive.com/news/dexcom-warns-of-scrapped-glucose-sensors-being-resold/821139/ XX XX   Beta Bionics plans to debut its first insulin patch pump by the end of the second quarter of 2027, subject to Food and Drug Administration clearance. The device, called Mint, would be compatible with Beta Bionics' interoperable automated glycemic controller, a software that allows for the pump to automatically adjust insulin delivery based on readings from a glucose sensor. Beta Bionics first unveiled the prototype for Mint last year at the American Diabetes Association's Scientific Sessions. The device is expected to have a similar size and wear time, at three days, to Insulet's patch pumps on the market. It would have a 200-unit insulin reservoir.   Mint differs by containing a mix of reusable and disposable components. Beta Bionics plans to make the device exclusively available in the pharmacy channel, building on its existing agreements for its current iLet insulin pump. Beta Bionics is one of several diabetes tech companies developing patch pumps to compete with market leader Insulet. Tandem Diabetes Care and Medtronic spinoff MiniMed have also announced planned patch pumps. Tandem said it plans to file a 510(k) submission this quarter for a tubeless version of its small, durable pump, and Medtronic plans to submit its patch pump to the FDA this fall.   https://www.medtechdive.com/news/beta-bionics-to-launch-its-first-insulin-patch-pump-to-compete-with-insulet/821091/ XX CVS puts Zepbound back on it's coverage list – with it's Caremark PBM. They also added Foundayo, Lilly's obesity pill. CVS had dropped Lilly's Zepound last summer but kept competitor Wegovy. It'll be back at Caremark October first. All three of the nation's largest pharmacy ⁠benefit managers ​now cover Lilly's full obesity medicine portfolio. https://www.reuters.com/legal/litigation/cvs-brings-back-coverage-lillys-obesity-drug-zepbound-2026-05-28/   More to come, including a new benefit from metformin for women, something new from Tidepool, big news for T1D in Austalia and more.. XX A new study suggests that higher long-term exposure to food colouring additives — including both synthetic and natural colourings commonly found in processed foods and beverages — may be associated with an increased risk of developing type 2 diabetes. Researchers analyzed data from more than 108,000 adults in the French NutriNet-Santé cohort between 2009 and 2023, following participants for a median of just over eight years. During that time, 1,131 participants developed type 2 diabetes. The study found that people with the highest intake of total food colouring additives had a 38% higher risk of developing type 2 diabetes compared with non- or low-consumers.   Several specific additives were linked to increased risk, including caramel colouring additives such as total caramel (E150 family), plain caramel (E150a), sulphite ammonia caramel (E150d), and beta-carotene (E160a). Additional associations were observed for curcumin (E100), anthocyanins (E163), paprika extract (E160c), lutein (E161b), and cochineal-derived colourings (E120). "Our findings revealed positive associations between widely consumed food colouring additives and type 2 diabetes incidence," the authors wrote, adding that further research is needed to better understand the mechanisms behind the findings and whether food colouring regulations should be reevaluated. https://www.medscape.com/viewarticle/use-common-food-colours-tied-high-type-2-diabetes-risk-2026a1000hes XX Big news for Australia – their Therapeutic Goods Administration (TGA) approves Tzield. Tzield is now approved in Australia to delay the onset of stage 3 (or clinical) T1D in people aged eight years and older with stage 2 T1D – the early, pre-symptomatic stage of the condition, where changes in blood glucose levels have begun but insulin therapy is not yet required. Breakthrough T1D Australia Chief Executive Officer, Sydney Yovic, said the approval represented a transformational moment for Australians affected by T1D. https://newshub.medianet.com.au/2026/05/landmark-approval-of-tzield-in-australia-ushers-in-a-new-era-of-delay-for-type-1-diabetes/155036/ XX https://www.theatlantic.com/health/2026/05/diabetes-pregnancy/687324/ XX A common diabetes drug may hold great potential to help with aging, even if scientists aren't exactly sure why. According to a study, the drug metformin doesn't just help patients to effectively manage their type 2 diabetes. it may also give older women a better chance of living to 90. Scientists in the US and Germany used data from a long-term US study of postmenopausal women.   Records for a total of 438 people were selected – half of whom took metformin to treat diabetes, and half of whom took a different diabetes drug, sulfonylurea.   While there are some caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. The study used age 90 as the marker for 'exceptional' longevity. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. RCTs could follow further down the line to dig deeper into these results, the researchers suggest. In the meantime, as the global population continues to skew older, studies continue to find ways to keep us healthier for longer and reduce damage to the body as we age. https://www.sciencealert.com/a-common-diabetes-drug-is-linked-with-exceptional-longevity-in-women XX The American Diabetes Association® (ADA) will host the 2026 Scientific Sessions from June 5-8 in New Orleans. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers, and healthcare professionals from around the globe. The premier diabetes meeting, which is also offered virtually, will feature the latest scientific findings in diabetes and obesity, where leading experts and peers will share findings in research for prevention, care, and cures at the Ernest N. Morial Convention Center. Key themes will include: Advancing obesity and metabolic health: Prevention, early detection, and disease modification: Improving cardiometabolic outcomes: Transforming care through innovation and access: New research will highlight how technology, artificial intelligence, and implementation strategies are reshaping diabetes care—reducing treatment burden, expanding access, and enabling more person-centered care. Advancing beta cell replacement and cure strategies: Fostering innovation: On Saturday, June 6, from 4:30-6:00 p.m., the Innovation Challenge, which debuted in 2023, invites emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determines which contestants will earn a private audience with potential funders. XX Tidepool, the nonprofit leader advancing innovation in diabetes technology, announced that Tidepool+ Direct Connect is now available through the Epic Showroom. Built on SMART on FHIR, Direct Connect brings interactive diabetes device data directly into Epic workflows, helping clinicians use patient data during routine care. "Tidepool has always focused on making diabetes data more accessible and actionable," said Brandon Arbiter, CEO. "We're excited to empower clinicians using Epic with insightful, intuitive patient data that fits directly into their encounter workflow so they can use it to improve care in the moment it matters."   Tidepool+ Direct Connect supports scalable deployment across Epic-enabled health systems. This architecture enables faster, more intuitive rollouts, enhancing Tidepool's existing EHR integration capabilities.   Direct Connect is part of Tidepool's ongoing work to improve how clinicians can use timely and relevant diabetes device data during patient visits to help drive better health outcomes.   The feature is now available in the Connection Hub of the Epic Showroom.   https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care XX

Former prime minister Tony Abbott didn't exactly disappear from the limelight after he lost his seat in the ‘teal' wave of 2019, but his new role as Liberal president has many asking: why is the party bringing him back now? Chief political correspondent Dan Jervis-Bardy speaks to Nour Haydar about how Abbott's appointment could change the party – and shape conservative politics in Australia

[powerpresss] My co-host Ken Suzan and I are welcoming you to episode 175 of our podcast IP Fridays! Today's interview guest is Bruce Dearling, patent attorney and partner at Hepworth Browne in the UK, and we talk about how non-technical features must be considered when assessing inventive step of patents at least according to recent decisions of the UK supreme court and the Unified Patent Court. Profile of Bruce Dearling UK Supreme Court Emotional Perception AI Limited UPC Abbot vs Sinocare But before we jump into this interesting interview, I have news for you: On May 20, 2026, the Swiss Federal Council adopted the fully revised Patent Ordinance, which will enter into force on January 1, 2027, together with the revised Patent Act. In the future, the Swiss Federal Institute of Intellectual Property will prepare a mandatory search report for each application; applicants can choose between a partially examined version and a full examination that assesses novelty and inventive step. The full examination costs an additional 300 Swiss francs, and renewal fees will increase by a total of eight percent over the 20-year term. On May 19, 2026, Asus entered into a licensing agreement with the Wi-Fi multimode patent pool managed by Sisvel, thereby ending all ongoing infringement proceedings. Sisvel bundles standard-essential patents in the pool from, among others, Atlantia, ETRI, and Mitsubishi Electric. On May 18, 2026, the UPC Local Chamber in Düsseldorf rejected Align Technology's application for a preliminary injunction against its Chinese competitor Angelalign. Angelalign may continue to sell its clear aligners within the UPC jurisdiction. Our partners Dirk Schulz, Ulrich Storz, and Wanze Zhang, together with Arnold Ruess, successfully represented Angelalign. The U.S. Patent and Trademark Office (USPTO) announced midweek that, since October of last year, it has invalidated or is seeking to invalidate approximately 10,500 trademark applications and registrations in eleven administrative orders. Reasons include forged attorney signatures and the fabrication of non-existent filing requirements. This stems from ongoing abuse of the U.S. trademark system, primarily by non-U.S. applicants, which can lead to conflicts with validly registered trademarks for legitimate businesses. On May 12, 2026, the British Court of Appeal overturned a lower court decision that would have required Nokia to grant interim licenses for video coding patents. The court found that Nokia's license offer to the Taiwanese manufacturers Acer and Asus had already been made on RAND terms. In May, the U.S. Department of Justice (DOJ) filed a brief in the ongoing Corteva v. Inari litigation, expressing antitrust concerns regarding certain patent practices in the field of plant breeding. This marks the first time the agency has actively intervened in a biopharmaceutical patent dispute with implications for seed innovations. Episode 175 of the IP Fridays podcast was a conversation I will not forget quickly. My guest Bruce Dearling, partner at Hepworth Brown in the UK and a patent attorney for 36 years, took a case through every level of the British court system up to the Supreme Court and, in doing so, fundamentally changed patent law for AI inventions in the UK. The case is called Emotional Perception, and its effects reach well beyond British borders. Below I summarize the key points from our conversation. The full episode is available at IP Fridays. A. What Is the Emotional Perception Case About? The underlying invention concerns artificial neural networks. Specifically, it relates to a method of closing what is called the semantic gap at the output of a neural network. That sounds abstract, but the idea is straightforward: a neural network always produces an output that does not fully correspond to what a human would actually expect or feel. Closing that gap brings the system closer to human perception and human expectations. Bruce Dearling drafted this application himself and filed it at the UK Intellectual Property Office (UKIPO). The Office rejected it as excluded subject matter, characterizing it as essentially a computer program as such. The legal basis for that rejection was the Aerotel decision from 2006. The case then went to the High Court, which found in favor of the applicant. The Court of Appeal reversed that decision. Then the UK Supreme Court stepped in and changed everything. B. The Aerotel Test and Its Flaws Since 2006, the Aerotel test had been the standard British method for assessing whether an invention falls within the excluded categories under patent law. It was a four-step approach: construe the claim, identify the actual contribution the invention makes to human knowledge, ask whether that contribution falls solely within excluded subject matter, and finally check whether the contribution is technical in nature. The problem Dearling described in our conversation is that Aerotel reverses the logical order of the analysis. You start with the contribution and only then ask about the exclusions under Article 52 EPC. The UK Supreme Court described Aerotel in its judgment as “unsound law” and overturned it. The EPO’s Technical Boards of Appeal had previously called Aerotel “disingenuous,” which at the time led to a public dispute between the British courts and the Boards. With the Emotional Perception ruling, that conflict has now been resolved in favor of harmonization with the EPO. C. What the UK Supreme Court Decided The Supreme Court made two central findings. First, the exclusion of computer programs “as such” is overcome as soon as a claim includes any piece of hardware. It does not matter whether that is a processor, a memory module, or any other component. The threshold is deliberately low. Dearling described this as the “any hardware” approach, which aligns fully with the EPO’s position following G1/19. Second, and in Dearling’s assessment the more important finding: when assessing inventive step, the invention must be considered as a whole. The Court introduced what it called an “intermediate step,” an analytical stage in which the interactions between all features of a claim are examined before the question of inventive step is addressed. Non-technical features cannot simply be struck out if they contribute to the overall technical effect of the invention. D. Inventive Step: The Intermediate Step This is the heart of the judgment. In EPO practice, Dearling said, it happens regularly that examiners strike through features they consider non-technical and thereby fail to assess the invention’s inventive step correctly. A recent Technical Board of Appeal decision, T 1249/22, already criticized this approach: a claim directed at a technical solution to a problem can be patentable even if the underlying problem is non-technical in nature. Dearling recalled a remark made by a Board of Appeal member at a hearing he attended years ago: “We understand that examining divisions can operate with a degree of mental laziness and that it’s too easy to throw too many things out of the basket when considering the issues of inventive step.” That quote stayed with him because it names a structural problem that the intermediate step now addresses directly. The British method for assessing inventive step is the Pozzoli test, which differs from the EPO’s problem-solution approach. The Supreme Court explicitly retained Pozzoli because the problem-solution approach, in its view, is structurally infected with hindsight reasoning: you already know the invention, you work backwards to formulate an objective technical problem, and then you ask whether it would have been obvious for the skilled person to arrive at precisely that solution. Dearling sees this as a source of unfairness toward genuine inventions. E. Alignment with the Unified Patent Court In April 2025, the Court of Appeal of the Unified Patent Court issued a decision in Abbott v. Sinocare (APP_000000901/2025, judgment of 17 April 2025). Dearling pointed out that this decision uses language and reasoning strikingly similar to the UK Supreme Court’s Emotional Perception ruling of February 2025. That is significant because the UPC is bound neither by UK courts nor by the EPO. The overlap suggests voluntary convergence. Dearling reported a conversation with a person close to the EPO, whom he did not name, who used the word “permissive” to describe the UK Supreme Court’s approach and indicated that the EPO might move toward it. Whether and how quickly that happens remains to be seen. What is clear is that the UPC, as the new European patent court, is setting its own standards, and the question of how to handle non-technical features in inventive step assessment is now being asked at multiple levels simultaneously. F. Implications for the EPO and Practice The EPO is not directly bound by the ruling. It is an administrative body, not a court. Dearling is nonetheless optimistic that change is coming. On one hand, external pressure is building: when the UK Supreme Court and the UPC articulate similar principles, convergence becomes hard to resist. On the other hand, Article 27.1 TRIPS requires all contracting states to make patents available in all fields of technology. Examiners routinely striking non-technical features from AI claims and rejecting them on that basis sits uncomfortably with that obligation. For the underlying application in the Emotional Perception case, the ruling has a pointed consequence. The Supreme Court did not grant the patent itself; it referred the matter back to the UKIPO for reconsideration under the intermediate step. The Office’s subsequent response was, in Dearling’s words, unconvincing. He suspects the Office is attempting to reintroduce the Aerotel test through the back door. As a last resort, he has not excluded a judicial review, a procedure that does not simply challenge the substantive decision but holds the Comptroller General of Patents to account for whether the Office is deliberately circumventing the Supreme Court’s direction on the intermediate step. That is, as Dearling put it, “a nuclear option,” but one he would not rule out if the evidence in the file already suggests the Office is in contempt of court. There is also an international dimension. Singapore’s Intellectual Property Office launched a public consultation shortly after the ruling, asking whether Singapore should adopt the Emotional Perception approach into national law. That is British soft power operating in real time within the Commonwealth. G. Three Takeaways for Patent Practitioners At the end of our conversation I asked Bruce Dearling to distill the most important practical points. His first takeaway: make sure the claim contains hardware. This applies not only to UK and European applications but is simply good drafting hygiene. Without hardware in the claim, the application remains exposed. The second takeaway concerns the description. Anyone filing an AI invention needs to explain clearly which function is achieved by which piece of hardware, circuit, or software. Not as boilerplate, but as a complete technical account that describes the real-world effects. Dearling’s experience is that practitioners who write the claim first and fill in the description afterward run into trouble. The third takeaway emerged from the conversation itself: how the EPO assesses inventive step for AI inventions is not a settled question. It is worth following the development of UPC case law and any shifts in EPO practice closely. Anyone advising on AI patent applications today needs to know these arguments. H. Conclusion The UK Supreme Court’s Emotional Perception ruling is not a British footnote. It has declared the Aerotel test dead, introduced the intermediate step that brings non-technical features back into the inventive step analysis, and set off a convergence movement that is already visible at the UPC and still pending at the EPO. For everyone working in AI patent practice, whether in prosecution, examination, or counseling, this ruling is required reading. Rolf Claessen: Our interview guest on IP Fridays podcast is Bruce Dearling. He has been in the IP field and a patent attorney for 36 years and is partner at Hepworth Brown in the UK. Thank you very much for being on the podcast. Bruce Dearling: My pleasure, Rolf. Thank you for inviting me. Rolf Claessen: All right. We just met at the INTA annual meeting in London. And you talked about the UK Supreme Court case where you were involved. And the core questions were whether non-technical features would be considered when assessing inventive step of patents. Can you briefly summarize this case? Bruce Dearling: It’s a bit more than that. It started — I actually wrote the case. And I prosecuted it through the patent office. The patent office rejected the case for being excluded subject matter. So pretty much the excluded subject matter provisions in the UK are nearly identical. They’re as near as practical to the language of the EPC, so those of the European Patent Office — Article 52.2. But again, they apply as such. The actual technology relates to artificial neural networks. And the invention related to a very clever way of what is termed closing the semantic gap at the output of the neural network. So that means that in a neural network, there is always a discrepancy between the output of the neural network in terms of what it’s telling you you should be thinking essentially, and what reality is. So if you can close the semantic gap, then you align the neural network or the artificial intelligence system to better reflect human knowledge or human reactions and human expectations. So that’s really what the invention is about. There’s no point in going into too much detail with it — that’s the way it is. It’s very clever. So the UKIPO rejected this because they said it was essentially a computer program excluded from patentability as such. And they used a decision which is called Aerotel, which has been around since 2006. And that decision has caused considerable consternation and tension between the EPO Technical Boards of Appeal and the UK courts. Aerotel was described as being essentially disingenuous by the EPO Technical Board of Appeal. And the UK courts pushed back and said, you don’t know what you’re talking about. So that’s where it fell apart. So that’s where they rejected it for essentially being a computer program as such, possibly with a bit of business methods thrown in as well. But let’s leave that for the time being. So the case then went to the High Court and at the High Court, we won. The judge said, actually, it’s not a computer program. Neural networks aren’t computers. They’re not programs themselves. There’s more to them than that. And the invention as claimed is not excluded from patentability as such. The UKIPO obviously weren’t very happy about that because they liked their Aerotel case and so they appealed it. And they appealed it on several grounds, including a new one, which was that it was a mathematical method. The Court of Appeal decided that the UKIPO was right and that we were wrong, so we lost the case. So we then went to the Supreme Court. Well, actually, they denied us an ability to go to the Supreme Court. The court said no appeal. We went — actually, no, I think there is a bigger issue here — because we realized, or I realized at that point, that the work that we were doing was much broader than this. It requires real consideration of what an invention is at a fundamental level. So not only exclusions, but how inventive step is applied. And these issues were built into the case from the very beginning. And they sort of — I wouldn’t say crept up on the court as we went through — but they became more and more prominent to the extent that ultimately, when we made an application to the Supreme Court, the Supreme Court went, yeah, we’ve got some issues here. We want to hear the full arguments on why this is not excluded from patentability, why Aerotel is potentially bad and how we more or less try to align ourselves with the European Patent Office. So that’s essentially what happened. And the Supreme Court hearing was last July. It took them the thick end of eight months to come out with a decision, which was issued in early February, at which point the entire legal landscape in the UK changed because they said we were right. The Patent Office doesn’t know what they’re talking about. Aerotel is bad. It’s unsound. That’s what they described it as — unsound law. It needs to be removed and we’re going to harmonize with the European Patent Office. So before I — I’m just going on a bit of a rant here, standing on my soapbox telling you what you already know. But the Aerotel test essentially was — it was a four-step test, past tense. So you firstly had to construe the claim. That’s pretty straightforward. Then you actually had to identify the actual contribution. This is what they said — identify the contribution. Really in this aspect, you’re asking what, as a matter of substance rather than form, the inventor has added to human knowledge. So that’s what they said the contribution was. And then they said, the next step in Aerotel was to ask, well, does that contribution fall solely within the excluded subject matter field or realm? And then they said, well, if you get through that question, then you check the actual contribution or the alleged contribution to see whether it’s technical in nature. So that’s the Aerotel test as it was. And what the Supreme Court in their unanimous final decision said was that Aerotel at best jumbles up the order. It reverses the logical order of the analysis by starting with the contributions and then addressing the Article 52 exclusions. And then finally it goes back to what the technical nature of the invention is about. So they really went, no, we don’t like any of this stuff. It’s bad, it’s stupid, it puts the cart before the horse. So, in the intervening period between finding the case and actually seeing it progress all the way to the Supreme Court, we obviously had the G1/19 decision from the EPO Enlarged Board. And they basically said that they are going to validate any hardware as the approach. And that’s essentially what the UK also went with. The UK Supreme Court said we’re going to say that the threshold of patentability — or the exclusion to patentability — is simply overcome by the inclusion in a claim of any piece of hardware, whether it’s a processor or a piece of memory or whatever. It doesn’t matter. Any hardware makes the invention a technical invention. So it’s a really low threshold to consider. And they then went, well, actually, if we now align and harmonize with the European Patent Office sensibly, then we need to look at how we assess inventive step, which is the other thing that we raised with the Supreme Court. In fact, we probably raised it at other times and in all the other instances as well, but it came to a head at the Supreme Court. So the Supreme Court then also went a bit further and said, well, actually, whilst we do like the global approach to assessing inventive step for all fields of technology — whether it’s chemistry or biotech or electronics or software or AI — we use a test called Pozzoli. So that isn’t problem-solution. We don’t like problem-solution. We think it’s not codified in the European Patent Office. It’s just a mechanism that the EPO has come up with to try to objectively assess inventive step. We don’t particularly think that’s appropriate. We like our approach called Pozzoli. That’s it. So we’re going to say with Pozzoli, however, in order to actually understand — particularly in the context of mixed inventions having technical and non-technical features — it’s necessary for the examiner to undertake the so-called intermediate step, where you have to look at the interactions between features within a claim. The invention is defined by the claim. That’s what the act says. That’s what everyone understands. It’s the invention defined by the claim. So you look at the claim features and then you have to understand the interactions that take place. And even if they are between technical and non-technical features, if they bring about an overall technical effect when you consider the invention as a whole, then your claim should be good and you can assess it for classical inventive step. So that’s really where we’re at. There’s a lot to unpack there already. It’s probably a podcast in its own right, but that’s the positive history of where we’re at. And I can keep going if you wish me to for a second and talk about why I think this is — we’ll just contrast it quickly with the problem-solution approach at the EPO and COMVIK. So for inventions in the computer-implemented field, they use COMVIK and the problem-solution approach. The Supreme Court said, as I said, they don’t like problem-solution. I think the problem-solution issue is that it is also inherently pre-baked with hindsight because you have to look at the invention and then step back and exclude those features which are common. And then you formulate a problem based on the function that the claim achieves. And then you’re asking whether or not it would be obvious for a skilled person to arrive at the claimed invention, having been given that hindsight-developed problem. So COMVIK is not great by any means. And we know from a practical perspective that examiners are only too willing to look at a claim and simply line through features which they believe are non-technical, whereas they don’t actually look at the interaction of those features in the context of the claim as a whole. There is also a decision — very recent one actually, about a year ago — T 1249/22, where the Technical Board of Appeal told the examiners and the examining division, you cannot do this. It’s okay to have a claim directed towards an invention in a non-technical field, as long as the invention is directed to a technical solution of that problem. I think it’s paragraphs 11 and 12 or 10 of that decision that are worth looking at. But they’re saying that in all fields of technology, it doesn’t matter as long as the technical solution is about technology — therefore, you should be able to obtain a patent as long as there is a realistic and appropriate technical effect. Be careful actually, Bruce — I don’t mean technical contribution, I mean technical effect. There’s a reason for that distinction. Rolf Claessen: The non-technical features are nevertheless used to assess inventive step in the UK now after this decision, right? Bruce Dearling: Yes, that is the intermediate step. The decision says you must look at the invention as a whole. It’s the important thing. There are a couple of issues that arise out of this. The first one is that you have to provide context for the invention. The Supreme Court never provided any specific guidance about how we deal with the intermediate step or what the exact test is, which is in some respects fine. It seems to be fairly clear that you just have to engage your gray matter — your neurons — to work out what is going on in the real world. And once you work out what’s going on in the real world, what the benefits are, then you look at whether or not the actual implementation of the invention fundamentally has a technical flavor to it, which is not just coding, not just simple coding, but it does something smarter. There’s a real technical impetus. There’s a technical effect. Now that actually brings me onto something I’ve postulated or said. I think the intermediate step will follow something like what I’ve termed the holistic character test, which essentially is: work out what’s going on in the real world. Then once you’ve worked out what’s actually being achieved, what the benefits are, what the invention’s concerned with, then you ask the question, how am I achieving it technically? And how is there a technical effect? How does the technical effect arise? That brings out a couple of issues. The first one is that it’s actually about the word “contribution” because it depends on how the word is used. So if you look at head note one in COMVIK, it uses the word “contribute” — how the non-technical feature contributes to the invention. So that’s an additive inclusive concept. The UK IPO historically, and arguably at the moment today whilst they’re trying to retrain their 400 examiners — which this has caused them to have to do — their idea of contribution is this backward-looking concept. So technical contribution and technical effect, I think — although we mix them up and interchange them — are distinct. Technical contribution: you’re looking backwards. Technical effect is what you look at when you look forward into what’s going on. So this is subtle — it’s really subtle, but it’s important. And once you realize that you are actually looking for the technical effects, then you’re on much safer ground. It’s much more objective in terms of the assessment. This might be somewhat contentious, because it’s the way I’m looking at this, but I’ve been working on this a long, long time and thinking about it for probably decades, worryingly so. So technical contribution and technical effects are probably not the same, where they are interchangeably used to mean the same thing within existing decisions. Rolf Claessen: And in the beginning you said, now that Aerotel is dead basically, it’s more harmonized with the EPO’s approach. But what I take from the discussion now is that maybe — especially in view of the problem-solution approach — it’s not fully harmonized with the EPO’s approach at the moment, right? Or did the UK Supreme Court get something wrong, or was that a desired outcome from your point of view that this is not so completely harmonized with the EPO? Bruce Dearling: Well, the EPO — the any-hardware solution is fully harmonized, no doubt. So it’s now a question of inventive step under Article 56 or Section 3 of the Act. The EPC nowhere mandates the use of problem-solution. And we know that there are many different ways of actually assessing inventive step, including the concrete elaboration test from last year and problem-of-invention approaches. So there are numerous ways of assessing inventive step. So the UK says, “Pozzoli — we like Pozzoli.” Interestingly, I had a discussion with someone I probably can’t mention. They’re saying that the UK approach may actually be more permissive now. It might even influence how the EPO operates. So they may move away from COMVIK towards more of a Pozzoli approach, which basically says this: You identify the notion of the skilled person — step one. You identify the common general knowledge of that skilled person — step one B. You identify the inventive concept of the claim in question, where you construe it if you can’t work out what it is. You then identify what the differences are. And then you ask the question, is it obvious to the skilled person, given knowledge of the common general knowledge? This is entirely not artificial because, as I said beforehand, when you look at problem-solution, you are formulating a problem by backtracking from what the claimed invention is to a situation where you say, well, these are the common features and I’m going to project a problem to try and solve. Now that is already tainted with hindsight reasoning. It’s not safe, it’s not thoroughly objective. There is an inherent problem with this which sees good inventions cast by the wayside. Although it’s a preferred mechanism, it’s not fully baked. There are situations where examiners are inherently lazy, or they just simply use something like the requirements specification argument, which is just factual. It just demonstrates that they can’t be bothered to actually argue it properly or think about what the invention is. Sorry to any examiners listening to this, but this is just my personal view, that sometimes there are problems. I’m reminded of a quote from an EPI hearing I was at a long time ago, where the Legal Board of Appeal member said: “We understand that examining divisions can operate with a degree of mental laziness and that it’s too easy to throw too many things out of the basket when considering the issues of inventive step.” Now that one has stayed with me because you think — did someone just say that? And the answer is yes, they did. But it just goes to show that there is some tension between the TBA and the examining divisions, and they don’t always get it right. Rolf Claessen: So there might be a small difference now between the UKIPO’s future approach of assessing inventive step and the EPO? Bruce Dearling: Yeah, it might do. But the other interesting thing here — and thank you for pointing this out, I hadn’t entirely caught up with it, I’ve been traveling beforehand and I missed some of the UPC case law. So the UPC case law — in, was it — yeah, we talked about that. Rolf Claessen: Yeah. There was a decision in April, Abbott versus Sinocare. Bruce Dearling: Yeah, 901 of 2025. So a Court of Appeal decision from the UPC. It was APP_000000901, I believe, 2025. Decision 17th of April, hearing 27th of March. The UPC is not bound by — it’s a court. The European Patent Office is not a court, it’s an agency that administers and looks after the administrative rule of law. So the fact that this decision came out from the UK Supreme Court in February, and you see almost identical language used in the UPC decision, suggests that there is some alignment here, or some convergence in thought. Now, whilst the UPC decision also references G1/19 and uses problem-solution, there is enough — you’ve got to bear in mind that high-level courts do look at each other’s decisions. And this is really a question of influence and the desire to converge. So the fact that they’ve done this at this time is quite interesting. Again, I can’t quote someone directly from the EPO, although I would love to. They were saying — at a very high level — and they used the words “converge UPC practice towards UK Supreme Court practice on interpretation of the law.” So this may actually be happening in real time. Again, it would be wrong to actually refer to anyone by name, but it’s an observation that when I looked at the case, I can see why this is going ahead. And I can see why the judiciaries — they want to maintain independent judicial controls. They won’t reference the UK Supreme Court decision, not least because we’re not in the UPC. But if you look at the arguments in sections 106 and 107 of the UK Supreme Court’s Emotional Perception decision and head note one, you go — wow, this is very close. Rolf Claessen: Very close and nearly identical wording. Yeah. And the UPC also now uses non-technical features for assessing inventive step. Is that a problem for the EPO that has historically been aggressive in throwing out non-technical features for inventive step analysis? Bruce Dearling: Well, I think they really need to get to the situation — I don’t know — this holistic character test that I’m sort of proposing, where you really have to think about what the invention is achieving, and then look at how it’s technically being achieved. And then if you look at that again in the context of that other decision I mentioned — T 1249/22 — it says something like, in the case of an invention that amounts to a technical implementation of a non-technical method, provided the non-technical method does not contribute to the technical character of the invention. The board validated the approach of identifying the non-technical method and then goes through and says it’s patentable. There are decisions like this which suggest that examining divisions have to give it a bit more thought, because the Technical Board will realize that to satisfy the WTO requirements — which pretty much everyone is bound by — Article 27.1 TRIPS, which requires that you protect all fields of technology. And that means whether it’s data processing or business methods, because business methods can be patentable so long as they are implemented on a technical basis. That essentially seems to be what T 1249/22 is saying, although it doesn’t explicitly say “allowing business methods.” The exclusion is only “as such.” So does this decision, in combination with the Supreme Court case and the movement of the UPC, say: well, actually, let’s look at this properly? It requires objective assessments, not just superficial “let’s strike through that feature because I don’t like it, it looks non-technical.” Rolf Claessen: So are you hopeful that the EPO is adjusting and will reshape their case law in view of the UPC decision and the UK Supreme Court decision? Bruce Dearling: It’s a bit unfortunate that the corresponding UK case at the EPO was dropped by the applicants, because it was heading towards an examination hearing at the examining division. It would have gone to the TBA, and I’m sure it would then have gone from the TBA to the Enlarged Board. I’m pretty sure that’s the case. There is another case from the same client which will probably argue the same thing because the specs are almost identical. It’s just lagged in time. So is it going to change? I hope so, because I think the EPO have got it wrong — more often than not in this field. Well, maybe not more often than not — they get it wrong more times than they should do. Would I like to see it changed? Yes, I would, because I want the examiners to actually think about the technology as opposed to just — oh, it’s not — I don’t want to engage the gray matter. That serves no one. That doesn’t serve technology. That doesn’t serve industry. These patent rights are there for a reason. They are property rights. I’m referring to the award of the 2025 Nobel Prize for Economics — they are a core driver for society’s development. So the 2025 Nobel Prize was for something called creative destruction — the replacement of old technology with new — and it’s based on the patent paradigm. So all this stuff is coming to a head now. It’s just a question of how quickly the EPO actually catch up, and maybe they have something to catch up on. It’s just understanding that the examiners have to start to think. As I said, we’ve got the issues at the UKIPO where they’re going to have to retrain 400 examiners. Rolf Claessen: Yeah, right. Bruce Dearling: The Emotional Perception case wasn’t granted by the Supreme Court. They referred it back to the patent office for consideration under the intermediate step. So the patent office produced a response that I would describe as — I’d say arguably — not well reasoned, which I’ve filed the response to, which basically says you don’t really know what you’re talking about. What really worries me a bit is that I think they’re trying to introduce the Aerotel case through the back door. It’s backsliding. It’s a mechanism for trying to apply it in a different way or a different context, which would be wrong. I think they believe that the applicant will appeal this if they get a bad decision — they will appeal it back to the courts again via the High Court, Court of Appeal, Supreme Court route. I say maybe not. I say maybe the client will file what they call a judicial review, which is a nuclear option. That’s when you actually hold the Comptroller General of Patents to account and get full discovery of whether or not there’s internal documentation showing that they are deliberately circumventing the direction of the Supreme Court on the intermediate step. This is basically holding them to account and saying: if you’re not applying the intermediate step appropriately, you are in contempt of the law. So judicial review is a really serious thing to do, but it’s certainly something I would not exclude from consideration. We’ll see what happens. It’s not saying we’re just going to go through the courts and make them decide on this. We’re going to say you’re wrong. And there’s already enough evidence in the files to suggest that they are probably in contempt of court and they’re not applying the intermediate step appropriately. They may not know any better at the moment — they need to be guided — but the consequences for them are potentially severe. Rolf Claessen: I have another question for you. You were the instructing attorney — do you think the decision was perfect? What argument that you made was the most underappreciated by the court? And where do you think the judgment got it wrong, or was it all perfect? Bruce Dearling: No, it got 90% or 95% correct. The intermediate step is right. That’s the most important thing in the decision — it’s the intermediate step. The any-hardware thing — that’s logical, that makes some sense — but if people say “if the any-hardware rule is the important bit,” no it isn’t. It’s the intermediate step. That’s the important thing. Where do they go wrong? I think they went wrong because — and you’ve got to bear in mind that unlike German courts, I’ve got to be careful about how I express this — generally, as I understand it, and correct me if I’m wrong, but the judiciary in Germany on patent cases are generally more technically able. They’re normally technically qualified. I look at the Supreme Court justices and the Court of Appeal justices — we had one who was a humanities undergrad, one was a chemist. Good luck with trying to argue complex artificial neural network technologies, which are difficult even for me to understand. And I’ve been working in the field. They’re hard to understand. They require real understanding, real appreciation. They could say, well, actually we don’t need to look at the technology — but frankly, if you’re looking at the statutes and exclusions to patentability and asking what a computer program is, then you need to understand what these technical terms really are. And if you can’t, then the judgment is potentially flawed. Their finding that the neural network is a computer program is, I think, technically obtuse. You know that the Singaporean government — the Intellectual Property Office of Singapore — released about six weeks ago a consultation note to the Singaporean profession and population, asking: is the Emotional Perception case right, and do we need to adopt it into Singaporean national law? So this is direct soft power from the UK Supreme Court changing Commonwealth legislation and statutes. We’ll see what happens. But from what I’ve seen of a draft response from the attorneys, they’re saying essentially: we agree any hardware is right, the intermediate step is right. The assessment of the neural network as a computer program is wrong, or it just doesn’t make any sense. And I’ve made the same comments before in SIPA, in the relevant round in March. There’s a disconnect. I mean, it’s like they equate a computer program with being able to be run on an analog computer. Now, an analog computer has no central processing unit. An analog computer just has resistors and transistors and capacitors. So if they’re saying that an analog computer can run a program — that’s essentially what they’re saying in part of the judgment. Where is the program in an analog computer? And if they’re saying it’s in the values of the resistors and the capacitors, then that has implications for any circuit we’ve got — it’s potentially a computer program — which is just madness, because it doesn’t sit well with the legislation and decisions we’ve looked at over the last 50 years. This is a real problem. It may be a storm in a teacup because you can overcome the objections by having any hardware, but it’s an argument they shouldn’t have been making. It seems to be abstract legal argumentation which has little credibility in my personal view, although it’s now law. It may be that someone can take that, have an argument with the Supreme Court, get them to fix this. The other thing is the EPO looks at a neural network as a mathematical method, and the UK now says it’s a computer program. Neither is right. The EPO is wrong as well. If you look at the actual decision which they regularly quote — the Vicom case — if you actually read the claim and look at the case, you see that it doesn’t make a huge amount of sense. A neural network has applied mathematics in it. It can be based on a computer program because it’s required to set up the learning objectives and the loss function. Mathematical processes — it tweaks the weighting factors of neurons over the course of the training epochs. But at the end of the day, if the function performed by the neural network is new and it’s directed towards a technical implementation which is technically relevant, then it shouldn’t fail for being a mathematical method. And I think the EPO guidelines actually say that. Even recommendations — the UK court said that a recommendation is not technical. Well, actually it is, because it’s data processing, and you’ve got to work out how does the data processing work to provide an improved recommendation? Again, it goes back to the T 1249/22 decision. There’s a whole raft of these things which are left not entirely resolved. There’s enough here to keep someone busy for a few more years. Rolf Claessen: Right. So I have a question for you now that we’ve talked about the decision of the UK Supreme Court and the UPC — the Unified Patent Court — with very, very similar wording. What do you say are the three most important takeaways for patent practitioners in the US, in Europe, in the UK, before the EPO? Are there any things that you really want patent practitioners to take away from our discussion here? Bruce Dearling: Yeah, okay. So first: make sure the claim has some structure in it. You need to have any hardware. That’s number one — in terms of claim drafting. In terms of the description, you really have to understand what the invention is about. And you’ve got to make sure that you explain what function is achieved by what piece of hardware, kit or software. And if you do that — don’t nickel-and-dime this by writing the claim first — I would suggest that you run into problems. You need to understand what the invention is about. And you need to make sure that the description is complete and full to describe the functionality and the effects that are achieved in the real world. And if you can do that, then you’re on a much sounder basis — much, much stronger. There’s a much stronger foundation for this. So that’s two things. Is there a third one? That’s me being a bit cheeky, but I suppose I know what’s going on. Rolf Claessen: Yeah, but maybe the third takeaway is that maybe the EPO will rethink the way — at least how AI inventions are assessed for inventive step. Bruce Dearling: Well, as I said to you before, it could be that that’s the case. I don’t want to repeat myself again. The word “permissive” was used in a conversation I had with respect to the UK Supreme Court approach. COMVIK fundamentally still breaks with me and has done for years, because the way it’s set up and the way it’s applied distorts fundamentally what the invention is about. And until such time as that distortion is removed, there is a problem of objectivity versus subjectivity. And I think that’s really what the EPO has to grapple with. It’s not an easy thing to deal with, but maybe there are things going on. Bruce Dearling: It’s not an easy thing to deal with. I don’t know who’s going to argue it. It would have been useful for me to still have the original case up and running at the EPO because these arguments would have been fleshed out. I’m pretty sure they would have been referred to the Enlarged Board. We would have got it resolved. So it’s whether or not I can now work this into the existing case to try and get the examining division to — well, they will refuse, I suspect. And then it’ll go to the TBA. And then the TBA will have to look at this, hopefully with the referrals to the Enlarged Board. And then that fixes the problem on a national and international basis. Rolf Claessen: Yeah. Let’s see. [Laughs] Bruce Dearling: No, we don’t know. I mean, you might have a different view. What do you think? Do you think COMVIK is fundamentally right or fundamentally wrong? Rolf Claessen: Well, I’m not so much into AI inventions. I’m a chemist and I usually deal with chemistry inventions. But from the discussion that we had, I think that the EPO might rethink their position. I don’t know. Let’s see. Let’s hope so. Bruce Dearling: Well, they liked it. They liked problem-solution. It’s been with us for 25 years. It suggests that it’s a compromise. It’s not mandated by the European Patent Convention — that’s the point. It’s something they think works. And these things only work until such time as someone comes along and says, actually, you’re wrong, and this is the reason. Rolf Claessen: Let’s see if they choose a different route at least for AI inventions. So Bruce, thank you very much for your insight and for talking about the case that you were involved in with the UK Supreme Court. Where could people reach you if they have more questions about this field — basically patents, AI protection in the UK and Europe — and if they want to ask you more questions about this case? Bruce Dearling: Sure. Through the Hepworth Brown website or my LinkedIn profile, I suppose. The Hepworth Brown website has an email link. I’m trying to post things on it as well to try and provide a bit more context. But if people have fundamental questions on this stuff, then I’m happy to try and answer them. I suppose that I can be considered to be quite knowledgeable in the area. Rolf Claessen: Right. Certainly more than I am. [Laughing] Bruce Dearling: So I was fortunate. As a consequence of the work I’m doing, I was appointed last year to the WIPO Standing Committee on Patents and Privacy. That was discussed for the issues of where WIPO goes and what the direction of the problems are that we have in high-tech areas. So there seems to be some degree of understanding that I might know what I’m talking about. I think I probably do. Rolf Claessen: Thank you, Bruce. Thank you very much for being on IP Fridays. Bruce Dearling: My pleasure. Thank you very much, Rolf.

Thomas Massie suffers a brutal Kentucky primary loss as conservatives react to his bitter concession speech and controversial comments that sparked backlash online. Scott Jennings, Dave Smith, and others weigh in while Trump shakes up Texas politics with a major endorsement of Ken Paxton.JD Vance dominates a fiery press conference, clashes with reporters, and shuts down new accusations against Trump as CNN and establishment Republicans continue to panic over the 2026 political landscape. We also break down shocking new election predictions in Texas, Arizona, Florida, and North Carolina.Plus: the San Diego mosque shooting investigation takes another turn after the alleged attackers' manifesto is released, Candace Owens reacts to the Hunter Biden interview buzz, Nick Shirley goes viral in the UK protests, and the internet erupts over the latest culture war stories involving TikTok, homelessness, sports, and gender ideology.SUPPORT OUR SPONSORS TO SUPPORT OUR SHOW!Register now for Bulwark Capital's FREE “Impact of Energy" live webinar May 21st at 3:30pm Pacific. https://KnowYourRiskPodcast.comHead to https://mudwtr.com/CHICKS to get an exclusive deal—up to 43% off your entire order, plus free shipping and a free rechargeable frother when you use code CHICKS. Our listeners get 10% off at StopBox when you use code THECHICKS at checkout. Head to https://StopBoxUSA.com Fresh Pressed Olive Oil gives you a FREE full-size $49 bottle for just $1 shipping—no commitment. Taste the difference at https://ChicksLoveOliveOil.comBecause readiness isn't just for the field—it's for life. Explore simple ways to stay prepared at https://ReadyWise.com and save 10% with Chicks10Subscribe and stay tuned for new episodes every weekday!Follow us here for more daily clips, updates, and commentary:YoutubeFacebookInstagramTikTokXLocalsMore InfoWebsite